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ABSTRACT  
Malaria is still a leading cause of mortality among children in the developing world, and despite 
the immense progress made in reducing the global burden, further efforts are needed if eradication 
is to be achieved. In this context, targeting transmission is widely recognized as a necessary 
intervention towards that goal. After carrying out a screen to discover new transmission-blocking 
agents, herein we report our medicinal chemistry efforts to study the potential of the most robust 
hit, DDD01035881, as a male-gamete targeted compound.  We reveal key structural features for 
the activity of this series and identify analogues with greater potency and improved metabolic 
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stability. We believe this study lays the groundwork for further development of this series as a 
transmission blocking agent. 
INTRODUCTION 
Malaria is one of the leading causes of infant mortality in the developing world, with nearly half 
a million children dying each year. It is caused by a eukaryotic protozoan parasite from the genus 
Plasmodium, of which P. falciparum is the most lethal. The parasite is transmitted to humans by 
the bite of a female Anopheles mosquito.1 Upon transmission, parasites invade hepatocytes and 
replicate, eventually being released into the bloodstream. The released parasites then invade 
erythrocytes to replicate asexually through a 48 h cycle during which all symptoms of the disease 
arise. A small percentage (0.2-1%) of parasites commit to sexual development, likely sequestered 
in the bone marrow, where they further develop through five morphological stages (Figure 1).2,3 
Mature, stage V, male and female gametocytes are then released into the blood stream where they 
remain relatively dormant, until being taken up by a mosquito during a subsequent blood meal, 
instigating host to vector transmission. Following feeding, gametocytes in the blood bolus become 
activated in the mosquito midgut, with male forms developing through a rapid 15-20-minute 
process of DNA replication and endomitosis to form 8 flagellated male gametes (a process termed 
exflagellation). Females in parallel round up and emerge from the infected red blood cell 
membrane. Fusion between gametes occurs within 24 hours, generating a motile zygote (called an 
ookinete), which traverses the midgut lining to eventually form an oocyst on the midgut wall. The 
oocyst goes through rounds of meiosis generating haploid parasite invasive forms, called 
sporozoites, which migrate to the mosquito salivary glands, ready to infect the next human, and 
therefore are responsible for the vector to host transmission of the disease.4 
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Figure 1. Host to vector transmission of Plasmodium. Following the commitment to sexual 
differentiation, gametocytes mature over five distinct morphological stages (I-V), maintaining 
quiescence from stages I-IV. Upon reaching maturation, stage V gametocytes withdraw from 
sequestration, entering the human bloodstream ready for transmission. In the event of a mosquito 
blood meal, male and female gametocytes rapidly transform into either 8 flagellated male 
microgametes or a single female macrogamete in the mosquito midgut. The fertilisation of haploid 
male and female gametes commences the onwards progression of the parasite lifecycle. Zygotes 
(ookinetes) traverse the mosquito midgut lining, leading to the eventual formation and migration 
of sporozoites to the salivary glands. The in vitro DGFA add-in (pink box) measures male 
gametocyte viability as the rate of exflagellation, or male gamete formation. 
Immense progress has been made from 2000 to 2015 in the reduction of the global malaria 
burden,5 thanks to the implementation of artemisinin combination therapies to reduce parasite 
numbers, together with the use of insecticide treated bed nets (ITNs) and indoor residual spraying 
(IRS) targeting the transmission of disease.6 However, the emergence of resistance (both to 
insecticides and frontline chemotherapeutics, including artemisinin and related compounds) 
threatens the gains made.7,8 If further progress is to be achieved towards eventual eradication of 
malaria, new drugs with new modes of action, including those able to stop disease transmission, 
will be needed.9,10 Transmission is a particularly attractive target for chemotherapeutic 
intervention since it represents a key parasite population bottleneck, compared with asexual stages, 
with only tens of sexual stage parasites responsible for transmission.11 Due to the low numbers of 
sexual stage parasites at a given time, and the fact that they are non-replicating stages, the 
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development of resistance to transmission-blocking drugs is predicted to be less likely. 
Additionally, the blockade of transmission provides a means to limit the spread of the expanding 
artemisinin drug-resistant strains.10 
Over the last decade a large amount of research has been devoted to the development of 
biochemical assays for the identification of compounds that target parasite transmission.12 While 
these efforts have provided new assays amenable to high-throughput screening (HTS), most of 
them only assess gametocyte viability; in contrast to the standard membrane feeding assay 
(SMFA),13 which evaluates the effectiveness of potential transmission-blocking drugs in vivo by 
studying changes in the numbers of oocysts in the mosquito midgut. Despite being considered the 
gold standard, and efforts to increase its throughput,14 the SMFA remains a costly and low-
throughput method, making it unsuitable for large scale compound identification campaigns. To 
address this challenge, a dual gamete formation assay (DGFA)15 was recently developed, which is 
amenable to HTS, emulating the conditions of the mosquito midgut in microtiter plate format in 
order to assess gametocyte development into gametes at scale. The DGFA has a sex-specific read-
out that allows for the identification of compounds with dual asexual-sexual, non-differentiating 
sexual and sex-specific activity, enabling identification of compounds that target aspects of 
biology unique to male and/or female gametocytes and gametes.16 Recently, some of us reported 
the use of the DGFA to screen a 70,000-compound Global Health Chemical Diversity Library 
(GHCDL) from the University of Dundee.17 The study represented the first example of a HTS 
campaign for the discovery of transmission-blocking agents carried out on a non-biased chemical 
library where transmission was the primary filter.  
The most robust hit identified from this screen was compound DDD01035881 (Figure 2). 
DDD01035881 is a fast acting, non-toxic male-gamete targeted compound with an in vitro EC50 
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value of approximately 200 nM, and an in vivo inhibition of oocyst formation higher than 99%, as 
determined using the SMFA when the compound was added 30 min before the mosquito feed at 
10 µM.17 The molecular target(s) of DDD01035881 is unknown. Five analogues of DDD01035881 
were reported in the initial disclosure,17 which provided limited information on the structure 
activity relationships (SAR) of this series; none of which had improved characteristics over the 
hit. Here we report a detailed medicinal chemistry study of this chemotype, exploring its potential 
for usage as a male-gamete targeted compound. We reveal key structure determinants for the 
activity of this series and identify compounds that are more potent than DDD01035881 and have 
improved metabolic stability. We believe this work should enable the further progression of this 
series as a transmission blocking therapy. 
 
Figure 2. Structure of male-gamete targeted hit DDD01035881 identified in the GHCDL screen.17 
RESULTS AND DISCUSSION 
Taking into consideration the structure of hit compound DDD01035881 and initially reported 
analogues (Figure S1), we decided to perform further SAR studies in order to assess the structural 
requirements for transmission-blocking activity. A summary of the features explored within this 
study is shown Figure 3.  
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Figure 3. Structural features considered of interest for the SAR study of DDD01035881. 
In order to study the effect of the changing the bromothiophene substituent, a synthetic route 
was developed, starting from 4-chromanone (Scheme 1). The addition of trimethylsilyl cyanide 
provided the protected cyanohydrin 1, which after reduction using lithium aluminium hydride 
(LAH) yielded the necessary aminoalcohol 2 in quantitative yield. Treatment of amine 2 with the 
sulfonyl chloride of the desired aromatic substituent afforded the first series of compounds 3-14. 
Compounds 3 and 4 are newly synthesised batches of DDD01035881 and DDD01028076 from 
the original report.17 
 
Scheme 1. Study of different aromatic substituents for the sulfonamide. Reagents and 
conditions: a) TMSCN, ZnI2, DCM, rt, 16 h, quant.; b) LAH, THF, rt, 16 h, quant.; c) ArSO2Cl, 
Et3N, DCM, rt, 16 h, 4-74%. *Ar groups can be reviewed in Table 1. 
Compounds 3-14 were evaluated using the DGFA, and the results are shown in Table 1. The 
EC50 value obtained for compound 4 is in agreement with the data from the HTS, while derivative 
3 shows a slight improvement when compared to the initial value,17 which could be explained due 
to experimental variability inherent to the DGFA assay coupled with differences in compound 
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purity. Compound 5, where the bromine atom has been moved to position 3 of the thiophene ring 
maintains the activity of 3. Movement of the bromine atom within a phenyl rather than thiophene 
ring has more impact however. For example, changing from the ortho- position in 4 to meta- in 6 
resulted in a >2.5 fold improvement in the activity, while the presence of a bromine atom at the 
para- position in 7 produced a complete loss of activity. Derivatives 8-10 containing a chlorine 
atom instead of a bromine atom show a similar trend. Removal of the halogen entirely does not 
result in a large decrease in activity (compound 11), while introduction of an electron withdrawing 
group such as a ketone at the meta- position is not tolerated (compound 14). In agreement with 
what was observed for halo- substitution, introduction of other groups at the para- position seems 
to be detrimental, regardless of their electronic properties (compounds 12 and 13). Taken together, 
this data suggests there is limited space available within this region the binding pocket of the 
(unknown) target(s) - particularly once the ring is expanded to a six-membered ring - with the 
para-position being particularly sensitive to substitution. 
Table 1. Modifications in the aromatic ring (Ar). 
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aBiological evaluation was carried out using the DGFA under the specific “add-in” format. 
Compounds were incubated at variable concentrations with fresh gametocytes, and their ability to 
impair exflagellation of male gametes determined. Values below 1 µM are expressed as the 
mean±SEM obtained from between three and eight biological replicates, each carried out in at least 
duplicate. bValue reported from initial HTS study.17 
As both 5-bromothiophene and meta-halobenzene rings in derivatives 3, 6 and 9 were able to 
produce the desired biological activity, we selected one of each for further SAR studies, 
specifically compounds 3 and 6 to maintain the identity of the halogen atom. To evaluate the 
importance of the sulfonamide linker, we synthesized derivatives 15-19, where the sulfonamide 
had been either methylated or replaced by an amide or amine group (Scheme 2). Treatment of 6 
with methyl iodide in the presence of potassium carbonate as base yielded methylsulfonamide 15 
in good yield. Preparation of amides 16 and 17 was performed from coupling of aminoalcohol 2 
to the desired carboxylic acid, in moderate yields, under standard coupling conditions of N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) and 1-hydroxybenzotriazole 
(HOBt) in the presence of an excess of triethylamine. Amines 18 and 19 were synthesized by 
reductive amination of the desired aromatic aldehyde using aminoalcohol 2 as the amine source. 
Picoline borane complex was selected as the reducing agent18 in the absence of acetic acid, to 
prevent elimination of the labile benzylic hydroxyl group.  
 9 
 
Scheme 2. Study of the sulfonamide liker. Reagents and conditions: a) MeI, K2CO3, DMF, 50 
ºC, 4 h, 80%; b) ArCOOH, EDC, HOBt, Et3N, DCM/DMF, rt, 16 h, 55-68%; c) ArCHO, 2-picoline 
borane, MeOH, rt, 24 h, 10-50%. 
All the attempted modifications to the linker resulted inactive compounds (Table S1). This 
highlights the importance of the sulfonamide group for activity. Interestingly, the fact that 
methylation of the sulfonamide in compound 15 renders loss of activity suggests that the NH group 
might be involved in a hydrogen-bonding interaction.  
Next, we conducted a preliminary study of substitution of the chromane ring. Substituents were 
selected based on commercial availability of the reagents and synthetic feasibility.  
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Scheme 3. Study of substitution in the core chromane scaffold. Reagents and conditions: a) 
TMSCN, ZnI2, DCM, rt, 16 h, 65-91%; b) LAH, THF, rt, 16 h, 23-70%; c) ArSO2Cl, Et3N, DCM, 
rt, 16 h, 28-90%; d) Pd(PPh3)4, K2CO3, MeOH, reflux, 16 h, 75%; e) allyl bromide, K2CO3, 
acetone, reflux, 16 h, 85%; f) 3-bromopropionic acid, NaH, DMF, rt, 16 h, 17%; g) Eaton’s 
reagent, rt, 16 h, 88%. 
As depicted in Scheme 3, the desired compounds were prepared from the corresponding 4-
chromanones, following an identical synthetic route to that shown in Scheme 1. In the case of 
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compound 37 with a free phenol group, commercially available 6-hydroxy-4-chromanone was 
protected with allyl bromide to avoid cross reactivity. Allylated derivative 36 was biologically 
tested, but also used to prepare phenol 37 by removal of the allyl chain in the presence of Pd(PPh3)4 
and potassium carbonate. 8-Methoxy-4-chromanone 21 was prepared from 2-methoxyphenol as 
previously described,19 but changing the reagent employed for the ring-closing Friedel-Crafts 
acylation from polyphosphoric acid (PPA) to Eaton’s reagent. The latter is preferred over PPA as 
it overcomes acknowledged practical issues associated with the handling of PPA such as its strong 
viscosity, difficulties in the reaction workup, or the need for extremely high temperatures.20 This 
alteration allowed us to increase the reported yield of 50% to 88%.  
Table 2. Study of substitution in the core scaffold. 




















































aBiological evaluation was carried out using the DGFA under the specific “add-in” format. 
Compounds were incubated at variable concentrations with fresh gametocytes, and their ability to 
impair exflagellation of male gametes determined. Values below 1 µM are expressed as the 
mean±SEM obtained from between three and eight biological replicates, each carried out in at least 
duplicate. 
All synthesised analogues resulted in a significant loss of activity, with the exception of 
fluorinated derivatives 38-41  (Table 2). Compounds 39 and 41 even show a slight improvement 
in potency over 6. Once again, these results suggest the binding site of this series within the 
target(s) to be reasonably confined. Indeed, in contrast to other substituents, fluorine is very similar 
in size to hydrogen, which could explain why analogues 38-41 retain activity. It should be 
highlighted that fluorine is widely used within drug discovery to improve permeability by 
increasing lipophilicity and to address pharmacokinetic issues such as oxidative metabolism,21 the 
latter being interesting in the context of this work (vide infra). 
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To further investigate the size constrains of the binding site, we next evaluated the outcome of 
modifying the size of the dihydropyran ring. Derivatives 51 and 52 with a seven-member ring, or 
analogues 54 and 55 containing a dihydrofuran were devised. The former analogues were 
synthesized from commercially available 2-hydroxyacetophenone (Scheme 4). Alkylation of the 
phenol with 1,2-dibromoethane, followed by enolate formation with sodium hydride and in situ 
ring closure by nucleophilic substitution of the bromine, provided the necessary ketone 48. 
Treatment of 48 with trimethylsilyl cyanide, followed by reduction with LAH as described for 
previous analogues, yielded aminoalcohol 50. Aminoalcohol 50 was reacted with the desired 
sulfonyl chlorides to afford benzoxepine derivatives 51 and 52. 
 
Scheme 4. Synthesis of the extended core scaffold analogues. Reagents and conditions: a) 1,2-
dibromoethane, K2CO3, ACN, reflux, 16h, 34%; b) NaH, THF, 0 ºC to rt, 16 h, 77%; c) TMSCN, 
ZnI2, DCM, rt, 16 h, 97%; d) LAH, THF, rt, 16 h, 35%; e) ArSO2Cl, Et3N, DCM, 0 ºC to rt, 16 h, 
38-63%. 
Preparation of dihydrofuran analogues 54 and 55 initiated from 3-coumaranone, following the 
same synthetic route shown for 4-chromanones. However, the typical conditions used for the 
formation of the cyanohydrin - trimethylsilylcyanide in the presence of catalytic zinc iodide - were 
unsuccessful, providing complex reactions mixtures. We speculate that lability of this scaffold to 
the Lewis acid was at fault and thus we attempted a different protocol that used potassium 
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carbonate as a catalyst instead.22 Unfortunately, these conditions also did not afford the desired 
cyanohydrin. Finally, the use of potassium phthalimide as catalyst in the absence of solvent 
provided mild enough conditions to allow for the formation of the desired cyanohydrin,23 which 
was reduced immediately due to stability issues to yield aminoalcohol 53 (Scheme 5). Treatment 
of 53 with the corresponding sulfonyl chlorides afforded final compounds 54 and 55. 
 
Scheme 5. Synthesis of the reduced core scaffold analogues. Reactants and reagents: a) i) 
TMSCN, potassium phthalimide, rt, 16 h; ii) LAH, THF, rt, 16 h, 35% (over two steps); b) 
ArSO2Cl, Et3N, DCM, 0 ºC to rt, 16 h, 51-53%. 
Expanding or contracting the central core resulted in a loss of activity (Table S2), being much 
more pronounced in the case of the seven-member ring analogues 51 and 52 (EC50>25 µM vs 
1>EC50>5 µM for 54 and 55). These results are in agreement with our previous data suggesting a 
small binding site within the target(s). The drop in activity observed for the smaller derivatives 54 
and 55, suggests that the geometry and size of the six-member ring is important for activity.  
Given that alteration in ring size was not tolerated, we evaluated whether the oxygen atom within 
the chromane scaffold was important for activity. We therefore prepared analogues 60 and 61 with 
a methylene unit, and 62 and 63 with sulfur replacing the oxygen. Scheme 6 shows the synthetic 




Scheme 6. Study of the importance of the oxygen atom. Reagents and conditions: a) TMSCN, 
ZnI2, DCM, rt, 16 h, 45%-quant; b) LAH, THF, rt, 16 h, 70-91%; c) ArSO2Cl, Et3N, DCM, rt, 16 
h, 33-75%. 
While compounds 60 and 61, with no heteroatom at all, displayed a complete loss of activity, 
derivatives 62 and 63, with a sulfur atom replacing the oxygen, showed a more moderate loss 
(EC50>25 µM and 1>EC50>5 µM, respectively, Table S3). This result is suggestive that polarity in 
this region of the series is important to retain activity. The loss of activity in the sulfur derivatives 
versus the oxygen derivatives can possibly be explained by the lower electronegativity of this 
element when compared to oxygen. Alternatively, it might just be that the larger size of sulfur is 
non-optimal. 
The final region of the series for exploration was the quaternary hydroxyl group. Given that this 
moiety is at a benzylic position could present a potential stability issue. To study this, we took 
compound 3 and submitted it to acidic conditions in order to get the product of the E1 elimination 
reaction, 64 (Scheme 7).  
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Scheme 7. Removal of the hydroxyl group in compound 3. Reagents and conditions: a) 
BF3·Et2O, DCM, 0 ºC, 1 h, 11%. 
The resulting alkene was found to be completely inactive in the DGFA assay (Table 3), 
suggesting that the hydroxyl group is required for transmission-blocking activity. An alternative 
option, however, would be that the geometry of the compound imposed by the alkene is not 
favoured. To investigate this further, we designed the saturated dehydroxylated analogues 68 and 
69, and derivatives 73 and 74 where hydroxyl group was methylated. As a final comparator, we 
designed compounds 76 and 77, where a fluorine atom replaced the hydroxyl group. 
For the preparation of analogues 68 and 69, we attempted to follow a similar strategy to the one 
shown in Scheme 7, followed by reduction of the alkene. Unfortunately, the yields were very low, 
and the conditions were not reproducible upon scale up. Therefore, we followed an alternate 
synthetic route (Scheme 8). Wittig reaction of 4-chromanone with 
methoxymethylenetriphenylphosphine, prepared in situ by deprotonation of the corresponding 
phosphonium salt with butyl lithium, yielded methyl vinyl ether 65 in good yield (86%). Cleavage 
of the methyl group using perchloric acid afforded aldehyde 66, which was directly used in the 
next step for the formation and in situ reduction of the corresponding oxime, to provide amine 67. 
Amine 67 was converted to 68 and 69 using the previously established chemistry. 
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Scheme 8. Preparation of the dehydroxylated derivatives. Reagents and conditions: a) 
(methoxymethyl)triphenylphosphonium chloride, BuLi, THF, -78 ºC to rt, 16 h, 86%; b) 70% 
HClO4, Et2O, 0 ºC to rt, 45 min, quant.; c) i) NH2OH·HCl, EtOH, rt, 45 min ii) Zn, HCl, rt, 15 
min, 33%; d) ArSO2Cl, Et3N, DCM, rt, 16 h, 43-68%. 
Analogues 73 and 74 were accessed from aminoalcohol 2, by protection of the amine followed 
by methylation of the hydroxyl group. Cleavage of the Boc protecting group from 71 and coupling 
to the corresponding sulfonyl chlorides gave the final compounds 73 and 74 (Scheme 9). It is worth 
noting that the Boc group required removal using tetrabutylammonium fluoride (TBAF) in 
refluxing THF,24 as compound 71 showed lability to commonly used acidic deprotection 
conditions (including TFA and HCl). Fluorinated derivatives 76 and 77, were obtained by 
replacement of the hydroxyl group in 2 by a fluorine atom using diethylaminosulfur trifluoride 
(DAST), followed by coupling of amine 75 to the desired sulfonyl chlorides. 
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Scheme 9. Synthesis of alkylated and fluorinated analogues. Reagents and conditions: a) Boc2O, 
Et3N, DCM, 0 ºC to rt, 5 h, quant.; b) MeI, K
tOBu, THF, 0 ºC to rt, 2 h, 70%; c) 1M TBAF in 
THF, reflux, 16 h, 39%; d) ArSO2Cl, Et3N, DCM, rt, 16 h, 44-84%; e) DAST, DCM, -78 ºC to rt, 
3 h, 31%. 
As shown in Table 3, the loss of activity observed for derivative 64 following elimination of the 
hydroxyl group does not seem to be due to the different geometry enforced by the alkene. Instead, 
it seems that the absence of the polar hydroxyl group is the issue, with saturated analogues 68 and 
69 also giving a complete loss of biological activity. Interestingly, the methylated derivatives 73 
and 74 retain comparable activity, which indicates that the hydroxyl group is not acting as a 
hydrogen-bond donor in the target(s). Finally, exchange of the hydroxyl group with a fluorine atom 





Table 3. Study of the importance of the hydroxyl group. 

































aBiological evaluation was carried out using the DGFA under the specific “add-in” format. 
Compounds were incubated at variable concentrations with fresh gametocytes, and their ability to 
impair exflagellation of male gametes determined. Values below 1 µM are expressed as the 
mean±SEM obtained from between three and eight biological replicates, each carried out in at least 
duplicate. 
As a final analysis of the importance of the hydroxyl group, we designed structurally isomeric 
compounds. Specifically, we elected to study compounds 78 and 79, in which the hydroxyl group 
had been retained at the benzylic position but the sulfonamide moved to the adjacent carbon. We 
also selected derivatives 80 and 81 with both substituents moved to the adjacent carbon. The 
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preparation of these analogues was envisioned through a common intermediate, alkene 82, by 
hydroboration-oxidation or epoxidation and ring opening, respectively (Figure 4). 
 
Figure 4. Schematic representation of the synthetic plan for the preparation of final compounds 
78-81. 
The synthesis of intermediate 82 was carried out by conjugate addition of 2-
hydroxybenzaldehyde to acrylonitrile followed by an intramolecular aldol condensation25 to yield 
83 (Scheme 10). Reduction of nitrile 83 and Boc protection of the resulting amine gave product 
82. 
 
Scheme 10. Synthesis of the necessary intermediate for the preparation of final compounds 78-
81. Reagents and conditions: a) acrylonitrile, DABCO, 90 ºC, 16 h, 74%; b) LAH, AlCl3, Et2O, 0 
ºC to rt, 2 h, 56%; c) Boc2O, Et3N, DCM, 0 ºC to rt, 5 h, 83%. 
Hydroboration-oxidation of alkene 82 was attempted using standard conditions, but complex 
reaction mixtures were obtained (Scheme 11). Careful following of the reaction by thin layer 
chromatography (TLC) showed that the oxidation step using hydrogen peroxide was responsible 
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for the observed decomposition, while the hydroboration step appeared to occur cleanly. Therefore 
sodium perborate was used as an oxidant instead,26 which, after some reaction optimization gave 
the desired anti-Markovnikov alcohol 85 in moderate yield (49%), showing the expected anti- 
stereochemistry as a result of the syn- addition of the borane to the double bond (Scheme 11). 
Surprisingly, the corresponding Markovnikov analogue 86 was also isolated in 27% yield. Since 
the latter is the product needed for the preparation of compounds 80 and 81, we progressed 86 
instead of performing the planned epoxide formation. 
 
Scheme 11. Hydroboration-oxidation of 82. Reagents and conditions: a) i) 1M BH3·THF, 0 ºC 
to rt, 2 h; ii) H2O2, NaOH, H2O, 0 ºC to rt, 16 h; b) i) 1M BH3·THF, 0 ºC to rt, 2 h; ii) NaBO3·4H2O, 
H2O, rt, 2 h, 27-49%. 
Boc deprotection of compound 85 had to be optimised for reaction temperature and time in order 
to avoid elimination of the benzylic alcohol to return unsaturated amine 84. However, 
epimerisation at the benzylic position could not be completely avoided, and the desired 
aminoalcohol was obtained as an inseparable 3:1 mixture of the anti- and syn- isomers 87a and 
87b as a result (Scheme 12). The mixture was treated with the corresponding sulfonyl chlorides, 




Scheme 12. Preparation of final compounds 78a,b and 79a,b. Reagents and conditions: a) TFA, 
DCM, 0 ºC, 30 min, 57%; b) ArSO2Cl, Et3N, DCM, rt, 16 h, 77-93%. 
With the conditions from removal of the Boc group optimised, derivatives 80 and 81 were 
prepared from 86 following a similar synthetic route (Scheme 13). 
 
Scheme 13. Preparation of final compounds 80 and 81. Reagents and conditions: a) TFA, DCM, 
0 ºC, 30 min, 33%; b) ArSO2Cl, Et3N, DCM, rt, 16 h, 15-70%. 
All six isomeric analogues were completely inactive (EC50>25 µM, Table S4), verifying the 
importance of the positioning of these substituents in the scaffold. While the relatively tight SAR 
displayed by this series is a challenge for ongoing medicinal chemistry, it may point to specificity 
for a given target(s), rather than promiscuous activity. 
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Up to this point, all compounds had been tested as racemic mixtures. To establish the role of 
absolute stereochemistry, we performed chiral resolution on a few of the most active derivatives.  
We selected the initial hit DDD01035881 (3) together with the bromobenzene analogue 6, one of 
the fluorinated compounds (41), and methoxylated derivative 74. Table 4 shows the results of this 
analysis, which demonstrates that one enantiomer is significantly more active than the other. In all 
cases, the (-) isomer is the active enantiomer. This result again suggests a specific biological 
interaction to underpin the activity of this series and showcases compounds with a potency of 18-
59 nM. While it would be ideal to assign the absolute stereochemistry of the active enantiomer, all 
attempts of crystallisation have been unsuccessful thus far.  
Table 4. Study of the activity of the enantiomeric pairs. 





















aBiological evaluation was carried out using the DGFA under the specific “add-in” format. 
Compounds were incubated at variable concentrations with fresh gametocytes, and their ability to 
impair exflagellation of male gametes determined. Values below 1 µM are expressed as the 
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mean±SEM obtained from between three and eight biological replicates, each carried out in at least 
duplicate. 
In vivo studies carried out on the original hit DDD01035881 provided a half-life of ~90 min for 
this compound.17 Taking into consideration the parasite lifecycle stage in which this scaffold 
intervenes, namely male gamete development in the mosquito midgut, longer circulation time 
would be required for the compound to be taken up by the mosquito. We hypothesised that the 
thiophene ring in the initial hit 3 might be one of the causes for the fast metabolism.27 For that 
reason, we decided to carry out in vitro metabolic stability studies on the most active compounds 
6, 39, 41 and 74, all bearing the bromobenzene ring instead. Additionally, compound 3 and its 
fluorinated analogue (38) were included for comparison. Table 5 shows the intrinsic clearance 
values (CLint) and half-life times (t1/2) obtained for compounds 3, 6, 38, 39, 41 and 74 when 
incubated with mouse liver microsomes. Surprisingly, changing the bromothiophene group to a 
bromobenzene ring does not impart metabolic stability: compound 6 is not detectable after 5 min 
of incubation with the microsomes, and bromobenzene derivative 39 has a reduced half-life of 
almost a minute when compared to its bromothiophene analogue (38). Compound 74 has a half-
life time comparable to that of compound 3, suggesting that the hydroxyl group is also not 
important for microsomal metabolism. Interestingly, fluorinated derivatives 38, 39 and 41 show a 
considerable improvement in stability, with almost a 4-fold reduction in microsomal clearance for 
compounds 38 and 41 versus compound 3. This result may suggest the chromane aromatic ring 
being a soft spot for oxidative metabolism. Oxidation of electron rich aromatic rings by 
cytochrome P450 (CYP450) to produce the corresponding phenol is well known, and fluorine is 
very commonly used to hamper such processes.21 Oxidation normally occurs at the more electron 
rich positions, i.e. ortho- and para- with respect to activating substituents, being the latter the most 
commonly found. In the case of compound 41, the most stable fluorinated analogue under 
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microsomal metabolism, the fluorine atom is at para- with respect to the alkyl chain and meta- 
with regard to the more activating ether substituent. Despite this, 41 shows a similar half-life than 
its analogue 39 where the fluorine atom is in para- to the ether oxygen. This may suggest that the 
increased microsomal stability of the fluorinated derivatives stems from general electronic tuning 
of the chromane ring, rather than blocking a specific metabolic soft spot on the aromatic ring. 
Table 5. Metabolic stability data for compounds 3, 6, 38, 39, 41 and 74 in mouse microsomes. 
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aBiological evaluation was carried out using the DGFA under the specific “add-in” format. 
Compounds were incubated at variable concentrations with fresh gametocytes, and their ability to 
impair exflagellation of male gametes determined. Values below 1 µM are expressed as the 
mean±SEM obtained from between three and eight biological replicates, each carried out in at least 
duplicate. bValues expressed as the mean from two to four experiments. cMetabolism was too fast 
to determine accurate values. 
The toxicity of four representative analogues against a human HepG2 cell line was evaluated as 
previously described.17 No cytotoxicity was observed for any of the assayed compounds after 48 
h of incubation, when compared to the drug doxorubicin, which was used as positive control (Table 
S5). 
CONCLUSIONS 
This study aimed to further explore the early medicinal chemistry of DDD01035881, the most 
robust hit identified from a 70,000-compound Global Health Chemical Diversity Library 
(GHCDL) screen using the DGFA assay.17 The ultimate aim of this project is to further the 
progression of compounds that can stop the transmission of malaria. In addition to a clearer 
understanding of the SAR of this series, we have identified a compound (41) with improved 
metabolic stability over the original hit and have clearly defined the active enantiomer of this 
series. While this certainly bodes well for further optimisation: ultimately a long circulating half-
live will be required in order for the optimised compound to reach its biological target in the 
mosquito. We note that drug delivery techniques may be another approach to extend the circulating 
half-life of this series. Taking advantage of the different environment found in the vector, namely 
the decrease in temperature to 28 ºC, temperature-controlled release from a drug delivery system 
may be possible; an approach more commonly exploited for hyperthermia.28 A final approach may 
be to use an optimised compound from this series as part of long-lasting ITNs or IRS. It has been 
recently shown that the antimalarial atovaquone can interrupt the parasite lifecycle completely in 
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the mosquito, after exposure of the Anopheles female to a glass surface coated with the drug.29 
This is an exciting study which opens new avenues for the development of transmission-blocking 
agents through perturbing biology in the mosquito, rather than the human host. 
EXPERIMENTAL SECTION 
Chemistry 
Unless otherwise stated, the starting materials, reagents, and solvents were purchased as high-
grade commercial products from Sigma-Aldrich, Acros, Alfa-Aesar, Fluorochem, TCI, or VWR. 
Solvents were either purchased anhydrous or dried by passing them through activated alumina 
columns using a Pure Solv™ Micro 100 Liter solvent purification system. All reactions were 
performed under nitrogen atmosphere. 
Analytical thin-layer chromatography was run on Merck silica gel plates (Kieselgel 60 F-254), 
with detection by UV light (=254 nm and 365 nm), ninhydrin or phosphomolybdic acid solutions 
in ethanol, or KMnO4 (aqueous, aq). Products were purified by flash chromatography on glass 
column with silica gel type 60 (particle size 40-63 u from Fluorochem). Optical rotation [was 
measured on a Bellingham and Stanley ADP 440+ polarimeter using a LED light source 
(interference filter, =589 nm) with a 0.5 dm path length; concentrations (c) are given as g/100 
mL. Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Avance III 400 MHz 
(1H, 400 MHz; 13C, 101 MHz; 19F, 377 MHz) instrument at room temperature (rt) at the NMR core 
facility at Imperial College London. Chemical shifts () are expressed in parts per million relative 
to internal tetramethylsilane; coupling constants (J) are in hertz (Hz). The following abbreviations 
are used to describe peak patterns when appropriate: s (singlet), d (doublet), t (triplet), q (quartet), 
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qt (quintet), m (multiplet), app (apparent), and br (broad). High resolution mass spectrometry 
(HRMS) spectra were recorded on a Micromass Autospec Premier and Micromass LCT Premier 
Spectrometer in electrospray ionization (ESI) mode at Imperial College London mass spectrometry 
core facility. For all final compounds, purity was determined by high-performance liquid 
chromatography coupled to mass spectrometry (HPLC-MS) using a Waters 2767 system. 
Separation was achieved using a XBridge C18 (5 μm, 4.6 mm × 100 mm) column, equipped with 
an XBridge C18 guard column (5 μm, 4.6 mm × 20 mm). The gradient mobile phase consisted of 
A (95:5 H2O/acetonitrile [ACN]) and B (5:95 H2O/ACN) with 0.1% formic acid as solvent 
modifier. Purity of tested compounds was at least 95%, unless stated otherwise. Spectra were 
acquired in positive or negative ionization mode from 100 to 1000 m/z and in UV-mode (scan 190-
700 nm). MS analysis was performed with an ESI source. Chiral resolution of selected compounds 
was performed by HPLC using either a Perkin Elmer Series 200 or an Agilent Thecnologies 1200 
Series system. Separation was achieved using a Chiralcel® OD-H or a Chiralpack® IE-3 column, 
with the corresponding guard columns. The mobile phase consisted of an isocratic gradient of 
hexane and isopropanol. 
All compound spectra are freely available at: https://doi.org/10.14469/hpc/5733 
GENERAL PROCEDURES 
A. Cyanohydrin formation 
To a stirred solution of the corresponding ketone (1 equiv) in dry DCM (3 mL/mmol) at 0 ºC, ZnI2 
was added (0.02 equiv) followed by trimethylsylilcyanide (1.5 equiv). The resulting mixture was 
allowed to warm up to rt and stirred at that temperature overnight. The reaction was diluted with 
DCM, washed with a saturated (sat.) solution of NaHCO3, dried over MgSO4, filtered and 
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evaporated under reduced pressure. The crude product was used in the next step without further 
purification. 
B. Cyanohydrin reduction 
To a stirred solution of the corresponding cyanohydrin (1 equiv) in anhydrous THF (4 mL/mmol) 
at 0 ºC, a 1M solution of LAH in THF (2 equiv) was added dropwise, and the resulting mixture 
was allowed to warm up to rt and stirred at that temperature overnight. The reaction was cooled 
down to 0 ºC and worked-up according to the Fieser-procedure. The crude was purified by flash 
chromatography using the appropriate eluent to afford the corresponding aminoalcohol. 
C. Sulfonamide formation 
To a stirred solution of the corresponding aminoalcohol (1 equiv) in dry DCM (4 mL/mmol) at 0 
°C, triethylamine (2.5 equiv) was added dropwise. Then, a solution of the desired sulfonyl chloride 
(1.1 equiv) in dry DCM (4 mL/mmol) was added and the reaction mixture was allowed to warm 
up to rt and stirred for 5 hours. Water was added and the mixture was extracted with DCM (2x), 
dried over MgSO4, filtered and evaporated under reduced pressure. The crude was purified by flash 
chromatography using the appropriate eluent to afford the desired product. 
D. Synthesis of N-((4-hydroxychroman-4-yl)methyl)amides 
To a solution of the corresponding carboxylic acid (1.1 equiv), EDC (1.5 equiv), and HOBt (1.5 
equiv) in dry DMF (5 mL/mmol of EDC/HOBt) at 0 °C, a solution of the corresponding 
aminoalcohol (1 equiv) in dry DCM (4 mL/mmol) was added followed by triethylamine (5 equiv). 
The mixture was stirred at 0 °C for 30 min, and then allowed to warm up to rt and stirred overnight. 
The reaction mixture was then diluted with DCM and washed with 5% LiCl (aq, 3x) and brine, 
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dried over MgSO4, filtered and evaporated under reduced pressure. The crude product was purified 
by flash chromatography using the appropriate eluent to afford the desired product. 
E. Synthesis of N-((4-hydroxychroman-4-yl)methyl)amines 
To a solution of 4-(aminomethyl)chroman-4-ol (1 equiv) in dry MeOH (15 mL/mmol), the 
corresponding aldehyde (1 equiv) was added and the solution was stirred for 15 min at rt, before 
2-picoline borane complex (1.2 equiv) was added portion wise. After stirring for 25 h, the reaction 
was dried over MgSO4, filtered and evaporated under reduced pressure. The crude product was 
purified by flash chromatography using the appropriate eluent to afford the desired product. 
4-((Trimethylsilyl)oxy)chromane-4-carbonitrile (1). Following general procedure A, 
cyanohydrin 1 was obtained from 4-chromanone (2.00 g, 13.3 mmol) in quantitative yield (3.3 g) 
as a colourless oil. 1H NMR (400 MHz, CDCl3) δ 7.56 (dd, J = 7.8, 1.6 Hz, 1H), 7.31 – 7.26 (m, 
1H), 6.98 (td, J = 7.8, 1.2 Hz, 1H), 6.84 (dd, J = 8.3, 1.1 Hz, 1H), 4.45 – 4.26 (m, 2H), 2.52 – 2.30 
(m, 2H), 0.17 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 153.7, 131.5, 128.8, 121.2, 120.9, 117.7, 
65.7, 61.4, 36.4, 1.3. Spectra available at: https://doi.org/10.14469/hpc/5801 
4-(Aminomethyl)chroman-4-ol (2). Following general procedure B, aminoalcohol 2 was 
obtained from cyanohydrin 1 (3.30 g, 13.3 mmol) in quantitative yield (2.4 g) as a pale-yellow oil. 
Column chromatography: DCM/7N NH3 in MeOH, 10:0 to 9:1. 
1H NMR (400 MHz, CDCl3) δ 
7.42 (dd, J = 7.8, 1.7 Hz, 1H), 7.18 (ddd, J = 8.2, 7.3, 1.7 Hz, 1H), 6.95 – 6.91 (m, 1H), 6.83 (dd, 
J = 8.2, 1.2 Hz, 1H), 4.30 – 4.20 (m, 2H), 3.07 (d, J = 13.1 Hz, 1H), 2.95 (d, J = 13.0 Hz, 1H), 
2.12 – 2.02 (m, 2H). 13C NMR (101 MHz, MeOD) δ 156.2, 130.2, 127.9, 127.5, 121.6, 118., 68.7, 
64.2, 51.0, 33.8. HRMS (ESI) calcd for [M+H]+ C10H13NO2 180.1025, found 180.1024. Spectra 
available at: https://doi.org/10.14469/hpc/5802 
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5-Bromo-N-((4-hydroxychroman-4-yl)methyl)thiophene-2-sulfonamide (3). Following 
general procedure C, sulfonamide 3 was obtained from aminoalcohol 2 (90 mg, 0.50 mmol) and 
3-bromobenzenesulfonyl chloride (90 mg, 0.50 mmol) in 52% yield (105 mg) as a white solid. 
Column chromatography: hexane/EtOAc, 4:1. 1H NMR (400 MHz, CDCl3) δ 7.35 – 7.29 (m, 2H), 
7.20 (ddd, J = 8.3, 7.2, 1.7 Hz, 1H), 7.06 (d, J = 3.9 Hz, 1H), 6.90 (td, J = 7.6, 1.2 Hz, 1H), 6.83 
(dd, J = 8.3, 1.2 Hz, 1H), 5.27 (t, J = 6.6 Hz, 1H, NH), 4.29 – 4.14 (m, 2H), 3.33 (d, J = 6.5 Hz, 
2H), 2.36 (ddd, J = 14.1, 6.3, 3.5 Hz, 1H), 2.29 (br s, 1H, OH), 2.03 (ddd, J = 14.1, 8.1, 4.3 Hz, 
1H). 13C NMR (101 MHz, CDCl3) δ 154.7, 141.5, 132.4, 130.6, 130.2, 126.4, 125.0, 121.1, 120.2, 
117.5, 68.4, 63.4, 51.6, 33.0. HRMS (ESI) calcd for [M-H]- C14H13NO4S2Br 401.9469, found 
401.9469. Spectra available at: https://doi.org/10.14469/hpc/5803 
Chiral resolution was performed on a Chiralcel® OD-H column using an isocratic gradient of 
hexane/isopropanol, 8:2 to yield (-)-3 and (+)-3. 
(+)-3:D
20 = + 48° (c = 0.125, MeOH) 
(-)-3:D
20 = - 48° (c = 0.125, MeOH) 
2-Bromo-N-((4-hydroxychroman-4-yl)methyl)benzenesulfonamide (4). Following general 
procedure C, sulfonamide 4 was obtained from aminoalcohol 2 (90 mg, 0.50 mmol) and 2-
bromobenzenesulfonyl chloride (141 mg, 0.55 mmol) in 67% yield (132 mg) as a white solid. 
Column chromatography: hexane/EtOAc, 4:1. 1H NMR (400 MHz, CDCl3) δ 8.10 (dd, J = 7.6, 1.9 
Hz, 1H), 7.76 (dd, J = 7.5, 1.6 Hz, 1H), 7.47 (td, J = 7.5, 1.5 Hz, 1H), 7.42 (td, J = 7.5, 1.9 Hz, 
1H), 7.32 (dd, J = 7.8, 1.6 Hz, 1H), 7.18 (ddd, J = 8.4, 7.3, 1.6 Hz, 1H), 6.88 (td, J = 7.8, 1.1 Hz, 
1H), 6.82 (dd, J = 8.3, 1.0 Hz, 1H), 5.55 (br t, J = 6.2 Hz, 1H), 4.30 – 4.15 (m, 2H), 3.20 (dd, J = 
6.7, 3.9 Hz, 2H), 2.43 (ddd, J = 14.1, 6.5, 3.7 Hz, 1H), 2.05 (m, 2H). 13C NMR (101 MHz, CDCl3) 
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δ 154.7, 138.6, 135.2, 134.0, 131.7, 130.1, 128.0, 126.4, 125.0, 121.0, 119.8, 117.4, 68.3, 63.4, 
51.5, 33.0. HRMS (ESI) calcd for [M-H]- C16H15NO4SBr 395.9905, found 395.9912. Spectra 
available at: https://doi.org/10.14469/hpc/5804 
3-Bromo-N-((4-hydroxychroman-4-yl)methyl)thiophene-2-sulfonamide (5). Following 
general procedure C, sulfonamide 5 was obtained from aminoalcohol 2 (90 mg, 0.50 mmol) and 
3-bromothiophene-2-sulfonyl chloride (144 mg, 0.55 mmol) in 60% yield (111 mg) as a white 
solid. Column chromatography: hexane/EtOAc, 4:1. 1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 
5.3 Hz, 1H), 7.33 (dd, J = 7.8, 1.6 Hz, 1H), 7.18 (ddd, J = 8.6, 7.3, 1.6 Hz, 1H), 7.11 (d, J = 5.3 
Hz, 1H), 6.89 (td, J = 7.8, 1.1 Hz, 1H), 6.81 (dd, J = 8.3, 1.0 Hz, 1H), 5.63 (t, J = 6.6 Hz, 1H, NH), 
4.29 – 4.13 (m, 2H), 3.31 (d, J = 6.7 Hz, 2H), 2.44 – 2.32 (m, 2H), 2.03 (ddd, J = 14.0, 8.0, 4.3 
Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 154.7, 135.8, 132.7, 131.2, 130.1, 126.4, 124.9, 121.0, 
117.5, 113.4, 68.3, 63.4, 51.6, 32.9. HRMS (ESI) calcd for [M-H]- C14H13NO4S2Br 401.9469, 
found 401.9476. Spectra available at: https://doi.org/10.14469/hpc/5805 
3-Bromo-N-((4-hydroxychroman-4-yl)methyl)benzenesulfonamide (6). Following general 
procedure C, sulfonamide 6 was obtained from aminoalcohol 2 (90 mg, 0.50 mmol) and 3-
bromobenzenesulfonyl chloride (141 mg, 0.55 mmol) in 42% yield (82 mg) as a white solid. 
Column chromatography: hexane/EtOAc, 4:1. 1H NMR (400 MHz, CDCl3) δ 7.98 (t, J = 1.9 Hz, 
1H), 7.75 (ddd, J = 7.9, 1.7, 1.1 Hz, 1H), 7.71 (ddd, J = 8.2, 1.9, 1.0 Hz, 1H), 7.39 (t, J = 7.9 Hz, 
1H), 7.29 (dd, J = 7.8, 1.7 Hz, 1H), 7.19 (ddd, J = 8.6, 7.3, 1.7 Hz, 1H), 6.88 (td, J = 7.6, 1.2 Hz, 
1H), 6.82 (dd, J = 8.4, 1.2 Hz, 1H), 5.23 (dd, J = 8.1, 4.9 Hz, 1H, NH), 4.31 – 4.11 (m, 2H), 3.39 
– 3.15 (m, 2H), 2.37 (ddd, J = 14.0, 6.3, 3.5 Hz, 1H), 2.31 (br s, 1H, OH), 2.02 (ddd, J = 14.0, 8.3, 
4.4 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 154.7, 141.9, 136.0, 130.9, 130.2, 130.0, 126.4, 125.6, 
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125.0, 123.4, 121.0, 117.5, 68.5, 63.5, 51.4, 32.9. HRMS (ESI) calcd for [M-H]- C16H15NO4SBr 
395.9905, found 395.9914. Spectra available at: https://doi.org/10.14469/hpc/5806 
Chiral resolution was performed on a Chiralcel® OD-H column using an isocratic gradient of 
hexane/isopropanol, 8:2 to yield (-)-6 and (+)-6. 
(-)-6: D
20 = - 87° (c = 0.53, DCM) 
(+)-6:D
20 = + 68° (c = 0.41, DCM) 
 4-Bromo-N-((4-hydroxychroman-4-yl)methyl)benzenesulfonamide (7). Following general 
procedure C, sulfonamide 7 was obtained from aminoalcohol 2 (90 mg, 0.50 mmol) and 3-
bromobenzenesulfonyl chloride (141 mg, 0.55 mmol) in 54% yield (107 mg) as a white solid. 
Column chromatography: hexane/EtOAc, 4:1. 1H NMR (400 MHz, CDCl3) δ 7.66 (app d, J = 8.8 
Hz, 2H), 7.62 (app d, J = 8.9 Hz, 2H), 7.25 (dd, J = 7.5, 1.9 Hz, 1H), 7.16 (ddd, J = 8.8, 7.3, 1.6 
Hz, 1H), 6.84 (td, J = 7.7, 1.2 Hz, 1H), 6.79 (dd, J = 8.3, 1.1 Hz, 1H), 5.47 (t, J = 6.6 Hz, 1H, NH), 
4.23 – 4.08 (m, 2H), 3.32 – 3.13 (m, 2H), 2.66 (s, 1H, OH), 2.31 (ddd, J = 14.0, 6.3, 3.5 Hz, 1H), 
1.98 (ddd, J = 13.8, 8.2, 4.3 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 154.6, 138.8, 132.6, 130.1, 
128.6, 127.9, 126.4, 125.0, 121.0, 117.4, 68.4, 63.4, 51.4, 32.8. HRMS (ESI) calcd for [M-H]- 
C16H15NO4SBr 395.9905, found 395.9915. Spectra available at: https://doi.org/10.14469/hpc/5807 
2-Chloro-N-((4-hydroxychroman-4-yl)methyl)benzenesulfonamide (8). Following general 
procedure C, sulfonamide 8 was obtained from aminoalcohol 2 (90 mg, 0.50 mmol) and 2-
chlorobenzenesulfonyl chloride (0.093 mL, 0.55 mmol) in 53% yield (93 mg) as a white solid. 
Column chromatography: hexane/EtOAc, 4:1. 1H NMR (400 MHz, CDCl3) δ 8.09 – 8.00 (m, 1H), 
7.58 – 7.48 (m, 2H), 7.41 (ddd, J = 8.5, 6.6, 2.1 Hz, 1H), 7.30 (dd, J = 7.8, 1.5 Hz, 1H), 7.17 (ddd, 
J = 8.6, 7.4, 1.6 Hz, 1H), 6.86 (td, J = 7.6, 1.0 Hz, 1H), 6.80 (dd, J = 8.3, 0.9 Hz, 1H), 5.53 (t, J = 
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6.6 Hz, 1H, NH), 4.28 – 4.11 (m, 2H), 3.27 – 3.11 (m, 2H), 2.43 – 2.37 (m, 2H), 2.02 (ddd, J = 
13.8, 8.0, 4.3 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 154.7, 137.0, 134.0, 131.8, 131.4, 131.4, 
130.1, 127.4, 126.4, 125.0, 121.0, 117.4, 68.3, 63.4, 51.5, 32.9. HRMS (ESI) calcd for [M-H]- 
C16H15NO4SCl 352.0410, found 352.0412. Spectra available at: https://doi.org/10.14469/hpc/5808 
3-Chloro-N-((4-hydroxychroman-4-yl)methyl)benzenesulfonamide (9). Following general 
procedure C, sulfonamide 9 was obtained from aminoalcohol 2 (90 mg, 0.50 mmol) and 3-
chlorobenzenesulfonyl chloride (0.083 mL, 0.55 mmol) in 57% yield (101 mg) as a white solid. 
Column chromatography: hexane/EtOAc, 4:1. 1H NMR (400 MHz, CDCl3) δ 7.83 (t, J = 1.9 Hz, 
1H), 7.72 (app d, J = 7.8 Hz, 1H), 7.56 (ddd, J = 8.0, 1.8, 0.9 Hz, 1H), 7.46 (t, J = 7.9 Hz, 1H), 
7.30 (dd, J = 7.7, 1.7 Hz, 1H), 7.19 (ddd, J = 8.6, 7.3, 1.7 Hz, 1H), 6.89 (td, J = 7.5, 1.2 Hz, 1H), 
6.82 (dd, J = 8.3, 1.2 Hz, 1H), 5.13 (dd, J = 8.4, 4.6 Hz, 1H, NH), 4.31 – 4.13 (m, 2H), 3.38 – 3.21 
(m, 2H), 2.39 (ddd, J = 14.0, 6.3, 3.4 Hz, 1H), 2.18 (br s, 1H, OH), 2.02 (ddd, J = 13.2, 8.6, 4.7 
Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 154.7, 141.7, 135.6, 133.1, 130.7, 130.2, 127.2, 126.4, 
125.2, 125.0, 121.0, 117.5, 68.5, 63.5, 51.5, 32.9. HRMS (ESI) calcd for [M-H]- C16H15NO4SCl 
352.0410, found 352.0406. Spectra available at: https://doi.org/10.14469/hpc/5809 
4-Chloro-N-((4-hydroxychroman-4-yl)methyl)benzenesulfonamide (10). Following general 
procedure C, sulfonamide 10 was obtained from aminoalcohol 2 (90 mg, 0.50 mmol) and 4-
chlorobenzenesulfonyl chloride (120 mg, 0.55 mmol) in 20% yield (28 mg) as a white solid. 
Column chromatography: hexane/EtOAc, 4:1. 1H NMR (400 MHz, CDCl3) δ 7.81 – 7.75 (m, 2H), 
7.53 – 7.46 (m, 2H), 7.29 (dd, J = 7.8, 1.6 Hz, 1H), 7.20 (ddd, J = 8.8, 7.3, 1.6 Hz, 1H), 6.89 (td, 
J = 7.7, 1.2 Hz, 1H), 6.83 (dd, J = 8.3, 1.1 Hz, 1H), 4.98 (dd, J = 8.4, 4.6 Hz, 1H), 4.30 – 4.15 (m, 
2H), 3.37 – 3.21 (m, 2H), 2.39 (ddd, J = 14.0, 6.3, 3.5 Hz, 1H), 2.17 – 1.97 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ 154.7, 139.5, 138.5, 130.2, 129.7, 128.6, 126.3, 125.1, 121.1, 117.5, 68.5, 
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63.5, 51.5, 33.0. HRMS (ESI) calcd for [M-H]- C16H15NO4SCl 352.0410, found 352.0405. Spectra 
available at: https://doi.org/10.14469/hpc/5810 
N-((4-Hydroxychroman-4-yl)methyl)benzenesulfonamide (11). Following general procedure 
C, sulfonamide 11 was obtained from aminoalcohol 2 (50 mg, 0.28 mmol) and benzenesulfonyl 
chloride (0.04 mL, 0.31 mmol) in 74% yield (66 mg) as a white solid. Column chromatography: 
DCM/1% NH4OH in MeOH, 98:2. 
1H NMR (400 MHz, CDCl3) δ 7.88 – 7.81 (m, 2H), 7.63 – 7.57 
(m, 1H), 7.56 – 7.50 (m, 2H), 7.29 (dd, J = 7.8, 1.6 Hz, 1H), 7.20 (ddd, J = 8.3, 7.3, 1.7 Hz, 1H), 
6.92 – 6.86 (m, 1H), 6.83 (dd, J = 8.3, 1.1 Hz, 1H), 4.86 (dd, J = 8.1, 4.9 Hz, 1H, NH), 4.30 – 4.14 
(m, 2H), 3.37 – 3.19 (m, 2H), 2.40 (ddd, J = 14.0, 6.4, 3.5 Hz, 1H), 2.06 – 1.97 (m, 2H, OH, 
½CH2).
 13C NMR (101 MHz, CDCl3) δ 154.8, 139.9, 133.0, 130.1, 129.4, 127.1, 126.4, 125.2, 
121.0, 117.5, 68.5, 63.5, 51.5, 33.0. HRMS (ESI) calcd for [M-H]- C16H16NO4S 318.0800, found 
318.0806. Spectra available at: https://doi.org/10.14469/hpc/5811 
N-((4-Hydroxychroman-4-yl)methyl)-4-methoxybenzenesulfonamide (12). Following general 
procedure C, sulfonamide 12 was obtained from aminoalcohol 2 (90 mg, 0.50 mmol) and 4-
methoxybenzenesulfonyl chloride (114 mg, 0.55 mmol) in 30% yield (52 mg) as a white solid. 
Column chromatography: hexane/EtOAc, 4:1. 1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 8.9 Hz, 
2H), 7.29 (dd, J = 7.8, 1.6 Hz, 1H), 7.17 (ddd, J = 8.3, 7.2, 1.7 Hz, 1H), 6.96 (d, J = 8.9 Hz, 2H), 
6.87 (td, J = 7.6, 1.2 Hz, 1H), 6.80 (dd, J = 8.2, 1.2 Hz, 1H), 5.07 (t, J = 6.7 Hz, 1H, NH), 4.26 – 
4.11 (m, 2H), 3.86 (s, 3H), 3.22 (d, J = 6.9 Hz, 2H), 2.39 – 2.33 (m, 2H), 2.00 (ddd, J = 14.0, 8.3, 
4.0 Hz, 1H). MS: m/z (ES) 348 [M-H]-. 13C NMR (101 MHz, CDCl3) δ 163.1, 154.7, 131.3, 130.0, 
129.3, 126.4, 125.3, 120.9, 117.4, 114.5, 68.4, 63.5, 55.8, 51.5, 33.0. HRMS (ESI) calcd for [M-
H]- C17H18NO5S 348.0906, found 348.0910. Spectra available at: 
https://doi.org/10.14469/hpc/5812 
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4-Cyano-N-((4-hydroxychroman-4-yl)methyl)benzenesulfonamide (13). Following general 
procedure C, sulfonamide 13 was obtained from aminoalcohol 2 (90 mg, 0.50 mmol) and 4-
cyanobenzenesulfonyl chloride (112 mg, 0.55 mmol) in 65% yield (111 mg) as a white solid. 
Column chromatography: hexane/EtOAc, 4:1. 1H NMR (400 MHz, CDCl3) δ 7.95 (d, J = 8.2 Hz, 
2H), 7.82 (d, J = 8.3 Hz, 2H), 7.30 (dd, J = 7.5, 1.9 Hz, 1H), 7.20 (ddd, J = 8.6, 7.3, 1.6 Hz, 1H), 
6.89 (td, J = 7.5, 1.2 Hz, 1H), 6.83 (dd, J = 8.3, 1.1 Hz, 1H), 5.51 (dd, J = 8.4, 4.5 Hz, 1H, NH), 
4.34 – 4.14 (m, 2H), 3.44 – 3.18 (m, 2H), 2.51 (s, 1H, OH), 2.37 (ddd, J = 14.0, 6.1, 3.4 Hz, 1H), 
2.04 (ddd, J = 13.3, 8.6, 4.7 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 154.7, 144.3, 133.2, 130.2, 
127.7, 126.3, 124.9, 121.0, 117.5, 117.4, 116.6, 68.5, 63.4, 51.5, 32.9. HRMS (ESI) calcd for [M-
H]- C17H15N2O4S 343.0753, found 343.0748. Spectra available at: 
https://doi.org/10.14469/hpc/5813 
3-Acetyl-N-((4-hydroxychroman-4-yl)methyl)benzenesulfonamide (14). Following general 
procedure C, sulfonamide 14 was obtained from aminoalcohol 2 (71 mg, 0.40 mmol) and 3-
acetylbenzenesulfonyl chloride (120 mg, 0.50 mmol) in 4% yield (6.3 mg) as a white solid. 
Column chromatography: hexane/EtOAc, 4:1. 1H NMR (400 MHz, CDCl3) δ 8.40 (t, J = 1.8 Hz, 
1H), 8.16 (app d, J = 7.8 Hz, 1H), 8.03 (app d, J = 7.8 Hz, 1H), 7.65 (t, J = 7.8 Hz, 1H), 7.29 (dd, 
J = 7.8, 1.7 Hz, 1H), 7.19 (ddd, J = 8.6, 7.3, 1.6 Hz, 1H), 6.88 (td, J = 7.6, 1.2 Hz, 1H), 6.83 (dd, 
J = 8.3, 1.2 Hz, 1H), 5.04 (dd, J = 8.7, 4.4 Hz, 1H, NH), 4.34 – 4.15 (m, 2H), 3.40 – 3.16 (m, 2H), 
2.65 (s, 3H), 2.41 (ddd, J = 14.0, 6.2, 3.5 Hz, 1H), 2.04 (ddd, J = 13.4, 8.1, 4.4 Hz, 1H), 1.61 (s, 
1H, OH). 13C NMR (101 MHz, CDCl3) δ 196.6, 154.7, 141.0, 138.1, 132.3, 131.2, 130.2, 129.9, 
126.8, 126.3, 125.0, 121.0, 117.5, 68.5, 63.5, 51.5, 33.0, 26.9. HRMS (ESI) calcd for [M-H]- 
C18H18NO5S 360.0906, found 360.0887. Spectra available at: https://doi.org/10.14469/hpc/5814 
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3-Bromo-N-((4-hydroxychroman-4-yl)methyl)-N-methyl benzenesulfonamide (15). To a 
stirred suspension of sulfonamide 6 (40 mg, 0.10 mmol) and K2CO3 (48 mg, 0.35 mmol) in DMF 
(1.5 mL), methyl iodide (14 L, 0.20 mmol) was added dropwise and the solution heated to 50 °C 
for 4 h. The mixture was diluted with EtOAc, washed with water (3x) and brine, dried over MgSO4, 
filtered and evaporated under reduced pressure. The resulting crude product was purified by flash 
chromatography (hexane/EtOAc, 3:1) to afford methylated sulfonamide 15 as a pale brown oil (36 
mg, 80%). 1H NMR (400 MHz, CDCl3) δ 7.90 (t, J = 1.8 Hz, 1H), 7.72 (ddd, J = 8.0, 1.9, 1.0 Hz, 
1H), 7.68 (ddd, J = 7.9, 1.7, 1.0 Hz, 1H), 7.40 (t, J = 7.9 Hz, 1H), 7.38 (dd, J = 7.8, 1.6 Hz, 1H), 
7.20 (ddd, J = 8.3, 7.3, 1.7 Hz, 1H), 6.91 (ddd, J = 7.7, 7.3, 1.2 Hz, 1H), 6.84 (dd, J = 8.3, 1.1 Hz, 
1H), 4.37 – 4.26 (m, 2H), 3.62 (d, J = 14.5 Hz, 1H), 3.11 (dd, J = 14.5, 0.7 Hz, 1H), 2.94 (s, 3H), 
2.57 (ddd, J = 14.0, 5.5, 3.1 Hz, 1H), 2.33 (s, 1H, OH), 2.10 (dddd, J = 13.9, 9.4, 4.4, 0.8 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 154.4, 139.3, 136.0, 130.8, 130.3, 129.9, 126.7, 126.2, 126.0, 
123.4, 120.9, 117.4, 70.0, 63.8, 58.6, 38.3, 33.2. HRMS, found 456.0117 (C18H19NO6S
79Br, [M-
OH + HCO2H]
+, requires 456.0116). Spectra available at: https://doi.org/10.14469/hpc/5815 
5-Bromo-N-((4-hydroxychroman-4-yl)methyl)thiophene-2-carboxamide (16). Following 
general procedure D, amide 16 was obtained from aminoalcohol 2 (80 mg, 0.45 mmol) and 5-
bromo-2-thiophenecarboxylic acid (104 mg, 0.55 mmol) in 55% yield (81 mg) as a white solid. 1H 
NMR (400 MHz, MeOD) δ 7.55 – 7.48 (m, 2H), 7.19 – 7.12 (m, 2H), 6.91 (td, J = 7.8, 1.2 Hz, 
1H), 6.77 (dd, J = 8.2, 1.1 Hz, 1H), 4.35 – 4.18 (m, 2H), 3.84 (d, J = 14.0 Hz, 1H), 3.62 (d, J = 
14.0 Hz, 1H), 2.12 (ddd, J = 14.0, 6.4, 3.2 Hz, 1H), 2.00 (m, ddd, J = 13.2, 9.1, 4.2 Hz, 1H). 13C 
NMR (101 MHz, MeOD) δ 163.7, 155.9, 141.8, 132.3, 130.2 130.1, 128.2, 127.6, 121.55, 119.2, 
117.8, 70.0, 64.6, 49.6, 49.4, 49.2, 49.0, 48.8, 34.2. HRMS (ESI) calcd for [M-H]- C15H13NO3SBr 
365.9756, found 365.9771. Spectra available at: https://doi.org/10.14469/hpc/5822 
 38 
3-Bromo-N-((4-hydroxychroman-4-yl)methyl)benzamide (17). Following general procedure 
D, amide 17 was obtained from aminoalcohol 2 (134 mg, 0.75 mmol) and 3-bromobenzoic acid 
(165 mg, 0.82 mmol) in 68% yield (184 mg) as a white solid. 1H NMR (400 MHz, MeOD) δ 7.99 
(app s, 1H), 7.78 (dd, J = 7.8, 0.9 Hz, 1H), 7.69 (dd, J = 8.0, 0.9 Hz, 1H), 7.53 (dd, J = 7.8, 1.3 
Hz, 1H), 7.38 (t, J = 7.9 Hz, 1H), 7.20 – 7.11 (m, 1H), 6.91 (dd, J = 10.7, 4.4 Hz, 1H), 6.78 (d, J 
= 8.2 Hz, 1H), 4.35 – 4.27 (m, 1H), 4.23 (ddd, J = 10.5, 6.5, 3.7 Hz, 1H), 3.88 (d, J = 13.9 Hz, 
1H), 3.68 (d, J = 13.9 Hz, 1H), 2.14 (ddd, J = 14.0, 6.5, 3.1 Hz, 1H), 2.02 (ddd, J = 13.2, 9.1, 4.0 
Hz, 1H).13C NMR (101 MHz, MeOD) δ 169.2, 155.9, 137.7, 135.6, 131.5, 131.4, 130.2, 128.2, 
127.6, 127.2, 123.5, 121.5, 117.8, 70.0, 64.6, 49.8, 34.3. HRMS (ESI) calcd for [M-H]- 
C17H15NO3Br 360.0235, found 360.0229. Spectra available at: https://doi.org/10.14469/hpc/5823 
4-((((5-Bromothiophen-2-yl)methyl)amino)methyl)chroman-4-ol (18). Following general 
procedure E, amine 18 was obtained from aminoalcohol 2 (90 mg, 0.50 mmol) and 5-
bromothiophene-2-carbaldehyde (0.06 mL, 0.50 mmol) in 50% yield (89 mg) as a colourless oil. 
1H NMR (400 MHz, MeOD) δ 7.41 (dd, J = 7.8, 1.6 Hz, 1H), 7.16 – 7.09 (m, 1H), 6.94 – 6.85 (m, 
2H), 6.75 (dd, J = 11.2, 2.5 Hz, 2H), 4.25 – 4.13 (m, 2H), 3.94, 3.90 (ABq, JAB = 14.4 Hz, 2H), 
2.92 (s, 2H), 2.36 (ddd, J = 13.9, 7.4, 4.2 Hz, 1H), 1.96 (ddd, J = 14.0, 6.7, 4.1 Hz, 1H). 13C NMR 
(101 MHz, MeOD) δ 156.2, 147.6, 130.7, 130.0, 128.0, 127.9, 126.8, 121.5, 117.8, 111.7, 69.1, 
64.3, 58.5, 49.6, 34.7. HRMS (ESI) calcd for [M-H]- C15H17NO2SBr 354.0163, found 354.0164. 
Spectra available at: https://doi.org/10.14469/hpc/5824 
4-(((3-Bromobenzyl)amino)methyl)chroman-4-ol (19). Following general procedure E, amine 
19 was obtained from aminoalcohol 2 (90 mg, 0.50 mmol) and 3-bromobenzaldehyde (0.06 mL, 
0.50 mmol) in 10% yield (18 mg) as a colourless oil. 1H NMR (400 MHz, MeOD) δ 7.52 (s, 1H), 
7.44 – 7.35 (m, 2H), 7.29 (d, J = 7.7 Hz, 1H), 7.23 (t, J = 7.7 Hz, 1H), 7.16 – 7.10 (m, 1H), 6.88 
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(td, J = 7.8, 0.9 Hz, 1H), 6.75 (dd, J = 8.3, 1.0 Hz, 1H), 4.27 – 4.11 (m, 2H), 3.80, 3.75 (ABq, J = 
13.7 Hz, 2H), 2.94 – 2.82 (m, 2H), 2.36 (ddd, J = 14.0, 7.6, 4.1 Hz, 1H), 1.96 (ddd, J = 14.0, 6.8, 
3.8 Hz, 1H). 13C NMR (101 MHz, MeOD) δ 156.2, 144.0, 132.3, 131.2, 131.1, 130.0, 128.2, 128.0, 
127.9, 123.4, 121.5, 117.8, 69.1, 64.3, 58.7, 54.2, 34.8. HRMS (ESI) calcd for [M-H]- 
C17H19NO2Br 348.0599, found 348.0606. Spectra available at: https://doi.org/10.14469/hpc/5825 
6-(Allyloxy)chroman-4-one (20). To a suspension of 6-hydroxy-4-chromanone (0.83 g, 5.1 
mmol) and K2CO3 (1.1 g, 7.6 mmol) in acetone (30 mL), allyl bromide (0.48 mL, 5.1 mmol) was 
added dropwise and the reaction was refluxed for 24 h. The resulting mixture was diluted with 
EtOAc and washed with sat. NH4Cl (3x). The combined aq. layers were extracted with EtOAc 
(2x). Combined organic phases were washed with brine, dried over MgSO4 and concentrated in 
vacuo. The crude product was purified by column chromatography (hexane/EtOAc, 9:1) to provide 
ketone 20 as a colourless oil (880 mg, 85%). 1H NMR (400 MHz, CDCl3) δ 7.23 (d, J = 3.2 Hz, 
1H), 7.03 (dd, J = 9.0, 3.2 Hz, 1H), 6.82 (d, J = 9.0 Hz, 1H), 5.97 (ddt, J = 17.2, 10.5, 5.3 Hz, 1H), 
5.35 (dq, J = 17.3, 1.6 Hz, 1H), 5.22 (dq, J = 10.5, 1.3 Hz, 1H), 4.45 – 4.40 (m, 4H), 2.72 – 2.69 
(m, 2H). 13C NMR (101 MHz, CDCl3) δ 191.7, 156.5, 152.8, 132.9, 125.5, 121.0, 119.1, 117.7, 
108.6, 69.2, 67.0, 37.6. HRMS (ESI) calcd for [M+H]+ C12H13O3 205.0859, found 205.0860. 
Spectra available at: https://doi.org/10.14469/hpc/5826 
8-Methoxychroman-4-one (21). Eaton’s reagent (15 mL) was added dropwise to a flask 
containing carboxylic acid 46 (600 mg, 3.10 mmol) and the mixture was stirred at rt overnight. 
The reaction was quenched with sat. NaHCO3, and the resulting mixture extracted with DCM (3x), 
dried over MgSO4, filtered and concentrated in vacuo to provide chromanone 21 as a yellow 
powder (480 mg, 88% yield). The spectroscopic data corresponds with those previously reported.19 
1H NMR (400 MHz, CDCl3) δ 7.52 (dd, J = 8.0, 1.6 Hz, 1H), 7.08 (dd, J = 8.0, 1.5 Hz, 1H), 6.98 
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(t, J = 8.0 Hz, 1H), 4.72 – 4.53 (m, 2H), 3.93 (s, 3H), 2.93 – 2.75 (m, 2H).  13C NMR (101 MHz, 
CDCl3) δ 191.8, 152.0, 149.0, 122.1, 120.9, 118.5, 116.8, 77.5, 77.2, 76.8, 67.8, 56.4, 37.8. HRMS 
(ESI) calculated for [M+H]+ C10H10O3 179.0708, found 179.0715. Spectra available at: 
https://doi.org/10.14469/hpc/5827 
6-Bromo-4-((trimethylsilyl)oxy)chromane-4-carbonitrile (22). Following general procedure A, 
cyanohydrin 22 was obtained from 6-bromo-4-chromanone (454 mg, 2 mmol) in 96% yield (626 
mg) as an orange oil which was used in the next step without further purification. 1H NMR (400 
MHz, MeOD) δ 7.60 (d, J = 2.4 Hz, 1H), 7.43 (dd, J = 8.8, 2.4 Hz, 1H), 6.80 (d, J = 8.8 Hz, 1H), 
4.44 – 4.24 (m, 2H), 2.47 (ddd, J = 13.1, 8.7, 4.4 Hz, 1H), 2.38 (ddd, J = 13.9, 5.5, 3.4 Hz, 1H), 
0.21 (s, 9H). 13C NMR (101 MHz, MeOD) δ 154.3, 135.3, 131.9, 124.5, 121.7, 120.9, 113.3, 66.7, 
62.9, 36.9, 1.2. Spectra available at: https://doi.org/10.14469/hpc/5828 
6-Fluoro-4-((trimethylsilyl)oxy)chromane-4-carbonitrile (24). Following general procedure A, 
cyanohydrin 24 was obtained from 6-fluorochroman-4-one (500 mg, 3.00 mmol) in 90% yield 
(718 mg) as a yellow oil, and used in the next step without further purification. 1H NMR (400 
MHz, CDCl3) δ 7.24 (dd, J = 8.6, 3.1 Hz, 1H), 6.99 (ddd, J = 9.1, 7.8, 3.1 Hz, 1H), 6.80 (dd, J = 
9.1, 4.6 Hz, 1H), 4.38 – 4.27 (m, 2H), 2.43 (ddd, J = 13.6, 8.0, 4.5 Hz, 1H), 2.35 (ddd, J = 13.8, 
5.7, 3.7 Hz, 1H), 0.23 (s, 9H).  Spectra available at: https://doi.org/10.14469/hpc/6020 
7-Fluoro-4-((trimethylsilyl)oxy)chromane-4-carbonitrile (25). Following general procedure A, 
cyanohydrin 25 was obtained from 7-fluorochroman-4-one (390 mg, 2.4 mmol) in 65% yield (405 
mg) as a colourless oil. Column chromatography: hexane/DCM, 4:1. 1H NMR (400 MHz, CDCl3) 
δ 7.52 (dd, J = 8.7, 6.2 Hz, 1H), 6.71 (ddd, J = 8.7, 8.0, 2.6 Hz, 1H), 6.56 (dd, J = 10.0, 2.6 Hz, 
1H), 4.40 – 4.28 (m, 2H), 2.46 – 2.32 (m, 2H), 0.18 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 164.3 
(d, J = 249.0 Hz), 155.0 (d, J = 12.7 Hz), 130.3 (d, J = 10.4 Hz), 120.9, 117.3 (d, J = 2.9 Hz), 
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108.6 (d, J = 22.4 Hz), 104.6 (d, J = 24.8 Hz), 65.2, 61.8, 36.2, 1.3. Spectra available at: 
https://doi.org/10.14469/hpc/5829 
8-Methoxy-4-((trimethylsilyl)oxy)chromane-4-carbonitrile (26). Following general procedure 
A, cyanohydrin 26 was obtained from chromanone 21 (460 mg, 2.6 mmol) in 91% yield (652 mg) 
and was used in the next step without further purification. 1H NMR (400 MHz, CDCl3) δ 7.19 (dd, 
J = 7.8, 1.6 Hz, 1H), 6.94 (t, J = 7.9 Hz, 1H), 6.89 (dd, J = 8.1, 1.6 Hz, 1H), 4.48 (ddd, J = 11.5, 
4.8, 4.0 Hz, 1H), 4.40 (ddd, J = 11.5, 9.8, 3.2 Hz, 1H), 3.88 (s, 3H), 2.48 – 2.36 (m, 2H), 0.17 (s, 
9H). 13C NMR (101 MHz, CDCl3) δ 148.6, 143.4, 121.4, 121.1, 120.5, 120.4, 112.6, 65.5, 61.9, 
56.2, 36.3, 1.3. Spectra available at: https://doi.org/10.14469/hpc/5830 
2-Phenyl-4-((trimethylsilyl)oxy)chromane-4-carbonitrile (27). Following general procedure A, 
cyanohydrin 27 was obtained from flavonone (500 mg, 2.23 mmol) in 12% yield (90 mg) as a light 
yellow oil, which and was used in the next step without further purification. 1H NMR (400 MHz, 
CDCl3) δ 7.58 (dd, J = 7.9, 1.6 Hz, 1H), 7.50 – 7.38 (m, 5H), 7.29 (ddd, J = 8.3, 7.3, 1.7 Hz, 1H), 
7.07 – 7.03 (m, 1H), 6.92 (dd, J = 8.3, 1.0 Hz, 1H), 5.40 (dd, J = 12.1, 1.7 Hz, 1H), 2.67 (dd, J = 
13.4, 1.8 Hz, 1H), 2.49 (dd, J = 13.4, 12.2 Hz, 1H), 0.30 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 
153.9, 139.1, 131.1, 129.0, 128.9, 127.6, 126.4, 122.6, 121.8, 121.4, 117.6, 75.9, 67.1, 43.9, 1.5. 
Spectra available at: https://doi.org/10.14469/hpc/5831 
4-(Aminomethyl)-6-bromochroman-4-ol (28). Following general procedure B, aminoalcohol 28 
was obtained from cyanohydrin 22 (652 mg, 2 mmol) in 23% yield (115 mg) as a colourless oil. 
Column chromatography: DCM/7N NH3 in MeOH, 98:2. 
1H NMR (400 MHz, MeOD) δ 7.57 (d, 
J = 2.5 Hz, 1H), 7.27 (dt, J = 7.1, 3.6 Hz, 1H), 6.72 (t, J = 7.5 Hz, 1H), 4.31 – 4.17 (m, 2H), 2.94, 
2.90 (ABq, JAB = 13.6 Hz, 2H), 2.23 (ddd, J = 14.1, 6.6, 3.6 Hz, 1H), 1.98 (ddd, J = 14.0, 8.1, 4.2 
Hz, 1H). 13C NMR (101 MHz, MeOD) δ 155.2, 132.8, 130.7, 130.7, 119.9, 113.3, 69.3, 64.6, 51.5, 
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33.0. HRMS (ESI) calcd for [M+H]+ C10H13NO2Br 258.0130, found 258.0134. Spectra available 
at: https://doi.org/10.14469/hpc/5832 
6-(Allyloxy)-4-(aminomethyl)chroman-4-ol (29). Following general procedures A and B, 
aminoalcohol 29 was obtained from ketone 20 (640 mg, 3.0 mmol) in 70% yield over two steps 
(630 mg). Column chromatography: DCM/7N NH3 in MeOH, 10:0 to 9:1. 
1H NMR (400 MHz, 
MeOD) δ 7.00 (d, J = 2.9 Hz, 1H), 6.77 (dd, J = 8.9, 3.0 Hz, 1H), 6.70 (d, J = 8.9 Hz, 1H), 6.04 
(ddt, J = 17.2, 10.5, 5.2 Hz, 1H), 5.38 (app dq, J = 17.3, 1.6 Hz, 1H), 5.23 (app dq, J = 10.7, 1.4 
Hz, 1H), 4.48 (dt, J = 5.1, 1.4 Hz, 2H), 4.20 – 4.11 (m, 2H), 2.90 (q, J = 13.6 Hz, 2H), 2.18 (ddd, 
J = 14.0, 7.0, 4.0 Hz, 1H), 1.94 (ddd, J = 14.0, 7.1, 4.2 Hz, 1H). 13C NMR (101 MHz, MeOD) δ 
153.9, 150.3, 135.2, 128.4, 118.5, 117.39, 117.35 113.5, 70.4, 69.6, 64.2, 51.8, 33.8. HRMS (ESI) 
calcd for [M+H]+ C13H18NO3 236.1282, found 236.1287. Spectra available at: 
https://doi.org/10.14469/hpc/5833 
4-(Aminomethyl)-6-fluorochroman-4-ol (30). Following general procedure B, aminoalcohol 30 
was obtained from cyanohydrin 24 (718 mg, 2.70 mmol) in 48% yield (253 mg) as a yellow solid. 
Column chromatography: DCM/10% NH4OH in MeOH, 8:2. 
1H NMR (400 MHz, MeOD) δ 7.15 
(dd, J = 9.6, 3.1 Hz, 1H), 6.90 (ddd, J = 9.0, 8.0, 3.1 Hz, 1H), 6.77 (dd, J = 9.0, 4.8 Hz, 1H), 4.25 
– 4.15 (m, 2H), 2.95 (d, J = 13.5 Hz, 1H), 2.89 (d, J = 13.6 Hz, 1H), 2.21 (ddd, J = 14.1, 6.6, 3.9 
Hz, 1H), 1.97 (ddd, J = 14.0, 7.5, 4.4 Hz, 1H). 13C NMR (101 MHz, MeOD) δ 156. 9 (d, J = 236.6 
Hz), 128.0 (d, J = 6.2 Hz), 117.6 (d, J = 7.8 Hz), 115.3 (d, J = 23.6 Hz), 112.4 (d, J = 23.6 Hz), 
67.9, 63.1, 50.1, 31.9. Spectra available at: https://doi.org/10.14469/hpc/6021 
4-(Aminomethyl)-7-fluorochroman-4-ol (31). Following general procedure B, aminoalcohol 31 
was obtained from cyanohydrin 25 (400 mg, 1.5 mmol) in 27% yield (80 mg) as a yellow oil. 
Column chromatography: DCM/7N NH3 in MeOH, 99:1 to 9:1. 
1H NMR (400 MHz, CDCl3) δ 
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7.37 (dd, J = 8.7, 6.6 Hz, 1H), 6.64 (ddd, J = 8.4, 2.6 Hz, 1H), 6.53 (dd, J = 10.2, 2.6 Hz, 1H), 4.31 
– 4.18 (m, 2H), 3.02 (d, J = 13.0 Hz, 1H), 2.92 (d, J = 13.0 Hz, 1H), 2.04 (t, J = 5.6 Hz, 2H). 13C 
NMR (101 MHz, CDCl3) δ 163.1 (d, J = 245.8 Hz), 156.2 (d, J = 12.2 Hz), 128.2 (d, J = 10.1 Hz), 
122.4 (d, J = 2.4 Hz), 108.2 (d, J = 21.8 Hz), 104.0 (d, J = 24.2 Hz), 67.5, 63.9, 50.8, 33.5. HRMS 
(ESI) calcd for [M+H]+ C10H12FNO2 198.0930, found 198.0930. Spectra available at: 
https://doi.org/10.14469/hpc/5834 
4-(Aminomethyl)-8-methoxychroman-4-ol (32). Following general procedure B, aminoalcohol 
32 was obtained from cyanohydrin 26 (600 mg, 2.2 mmol) in 34% yield (154 mg) as a white 
powder. Column chromatography: DCM/7N NH3 in MeOH, 95:5 to 9:1. 
1H NMR (400 MHz, 
CDCl3) δ 7.04 (dd, J = 7.9, 1.5 Hz, 1H), 6.89 (t, J = 8.0 Hz, 1H), 6.80 (dd, J = 8.0, 1.4 Hz, 1H), 
4.40 – 4.27 (m, 2H), 3.87 (s, 3H), 3.07 (d, J = 13.1 Hz, 1H), 2.94 (d, J = 13.1 Hz, 1H), 2.14 – 2.02 
(m, 2H). 13C NMR (101 MHz, CDCl3) δ 148.5, 144.5, 127.0, 120.3, 118.3, 110.7, 67.9, 63.9, 56.1, 
50.9, 33.5. HRMS (ESI) calcd for [M+H]+ C11H15NO3 210.1130, found 210.1126. Spectra 
available at: https://doi.org/10.14469/hpc/5835 
4-(Aminomethyl)-2-phenylchroman-4-ol (33). Following general procedure B, aminoalcohol 33 
was obtained from cyanohydrin 27 (85 mg, 0.26 mmol) in 61% yield (41 mg) as a white solid after 
trituration of the crude with diethylether. 1H NMR (400 MHz, MeOD) δ 7.49 – 7.45 (m, 3H), 7.40 
– 7.36 (m, 2H), 7.31 (ddd, J = 7.2, 3.6, 1.3 Hz, 1H), 7.18 (ddd, J = 8.3, 7.4, 1.7 Hz, 1H), 6.95 (td, 
J = 7.7, 1.1 Hz, 1H), 6.85 (dd, J = 8.2, 1.0 Hz, 1H), 5.15 (dd, J = 12.6, 1.9 Hz, 1H), 3.19 (d, J = 
13.5 Hz, 1H), 3.08 (d, J = 13.5 Hz, 1H), 2.40 (dd, J = 13.9, 2.2 Hz, 1H), 2.17 (ddd, J = 13.7, 12.7, 
0.8 Hz, 1H), 1.93 (s, 2H, NH2). 
13C NMR (101 MHz, MeOD) δ 154.7, 140.9, 129.8, 129.0, 128.6, 
127.0, 126.7, 126.5, 121.3, 117.1, 76.4, 68.9, 50.0, 40.1. HRMS (ESI) calcd for [M+H]+ 
C16H18NO2 256.1338, found 256.1339. Spectra available at: https://doi.org/10.14469/hpc/5836 
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5-Bromo-N-((6-bromo-4-hydroxychroman-4-yl)methyl)thiophene-2-sulfonamide (34). 
Following general procedure C, sulfonamide 34 was obtained from aminoalcohol 28 (26 mg, 0.10 
mmol) and 5-bromothiophene-2-sulfonyl chloride (40 mg, 1.5 mmol) in 83% yield (40 mg) as a 
white solid. Column chromatography: petroleum ether/Et2O, 1:2. 
1H NMR (400 MHz, CDCl3) δ 
7.51 (d, J = 2.5 Hz, 1H), 7.37 (d, J = 4.0 Hz, 1H), 7.25 (dd, J = 8.8, 2.5 Hz, 1H), 7.16 (d, J = 4.0 
Hz, 1H), 6.69 (d, J = 8.8 Hz, 1H), 4.29 – 4.15 (m, 2H), 3.31 (ddd, J = 9.4, 8.0, 7.6 Hz, 3H), 3.18 
(d, J = 13.4 Hz, 1H), 2.31 (ddd, J = 14.1, 6.0, 3.8 Hz, 1H), 1.96 (ddd, J = 13.4, 8.3, 5.1 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 155.2, 144.2, 133.1, 132.0, 131.1, 129.6, 120.0, 119.9, 113.4, 68.6, 
64.6, 52.7, 33.5. HRMS (ESI) calcd for [M-H]- C14H12NO4SBr2 479.8574, found 479.8586. 
Spectra available at: https://doi.org/10.14469/hpc/5837 
3-Bromo-N-((6-bromo-4-hydroxychroman-4-yl)methyl)benzenesulfonamide (35). Following 
general procedure C, sulfonamide 35 was obtained from aminoalcohol 28 (26 mg, 0.10 mmol) and 
3-bromobenzenesulfonyl chloride (31 mg, 0.12 mmol) in 90% yield (43 mg) as a white solid. 
Column chromatography: petroleum ether/Et2O, 1:2. 
1H NMR (400 MHz, MeOD) δ 7.98 (t, J = 
1.8 Hz, 1H), 7.80 (app ddd, J = 7.8, 1.4, 1.0 Hz, 1H), 7.76 (app ddd, J = 8.1, 1.8, 0.9 Hz, 1H), 7.54 
– 7.40 (m, 2H), 7.22 (dd, J = 8.8, 2.5 Hz, 1H), 6.68 (d, J = 8.8 Hz, 1H), 4.25 – 4.17 (m, 2H), 3.27 
(d, J = 13.4 Hz, 1H), 3.11 (d, J = 13.4 Hz, 1H), 2.36 – 2.28 (m, 1H), 1.99 – 1.90 (m, 1H). 13C NMR 
(101 MHz, MeOD) δ 155.2, 144.2, 136.5, 133.1, 132.0, 131.0, 130.6, 129.6, 126.6, 123.8, 119.8, 
113.3, 68.7, 64.5, 52.5, 33.4. HRMS (ESI) calcd for [M-H]- C16H14NO4SBr2 473.9010, found 
473.9025. Spectra available at: https://doi.org/10.14469/hpc/5838 
N-((6-(Allyloxy)-4-hydroxychroman-4-yl)methyl)-3-bromobenzenesulfonamide (36). 
Following general procedure C, sulfonamide 36 was obtained from aminoalcohol 29 (540 mg, 2.3 
mmol) and 3-bromobenzenesulfonyl chloride (980 mg, 3.4 mmol) 53% yield (558 mg). Column 
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chromatography: hexane/EtOAc, 7:3. 1H NMR (400 MHz, DMSO) δ 7.97 (t, J = 1.7 Hz, 1H), 7.88 
(br s, 1H, OH), 7.84 (ddd, J = 8.0, 1.8, 0.9 Hz, 1H), 7.80 (ddd, J = 7.8, 1.4, 0.8 Hz, 1H), 7.53 (t, J 
= 7.9 Hz, 1H), 6.91 (d, J = 3.0 Hz, 1H), 6.75 (dd, J = 8.9, 3.0 Hz, 1H), 6.69 (d, J = 8.9 Hz, 1H), 
6.00 (ddt, J = 17.2, 10.5, 5.2 Hz, 1H), 5.39 – 5.33 (m, 2H, NH, ½CH2=), 5.21 (dq, J = 10.5, 1.6 
Hz, 1H), 4.49 – 4.40 (m, 2H), 4.13 – 4.06 (m, 2H), 3.13 (d, J = 13.3 Hz, 1H), 2.97 (d, J = 13.2 Hz, 
1H), 2.19 (ddd, J = 13.8, 6.4, 3.6 Hz, 1H), 1.82 (ddd, J = 12.1, 7.5, 4.1 Hz, 1H). 13C NMR (101 
MHz, DMSO) δ 151.7, 148.2, 142.9, 135.1, 134.1, 131.3, 128.9, 127.3, 125.5, 122.0, 117.0, 116.8, 
115.8, 112.9, 68.6, 67.1, 62.6, 51.1, 32.4. HRMS (ESI) calcd for [M-H]- C19H19NO5SBr 452.0167, 
found 454.0161. Spectra available at: https://doi.org/10.14469/hpc/5839 
3-Bromo-N-((4,6-dihydroxychroman-4-yl)methyl)benzene-sulfonamide (37). To a solution of 
compound 36 (530 mg, 1.2 mmol) in MeOH (20 mL), Pd(PPh3)4 (135 mg, 0.3 mmol) was added 
and the mixture stirred for 10 min. K2CO3 (481 mg, 3.5 mmol) was then added and the reaction 
was refluxed for 16 h. The resulting solution was concentrated in vacuo, taken up in DCM, washed 
with H2O (3x), extracted with DCM (2x), washed with brine, dried over MgSO4 and concentrated 
in vacuo. The crude product was purified by column chromatography (hexane/EtOAc, 1:1) to yield 
phenol 37 as a white solid (356 mg, 75%). 1H NMR (400 MHz, DMSO) δ 8.84 (s, 1H, OH), 7.98 
(t, J = 1.8 Hz, 1H), 7.87 – 7.82 (m, 2H, OH, CH), 7.80 (ddd, J = 7.8, 1.4, 0.9 Hz, 1H), 7.53 (t, J = 
7.9 Hz, 1H), 6.71 (t, J = 1.5 Hz, 1H), 6.55 (d, J = 1.5 Hz, 2H), 5.33 (s, 1H, NH), 4.10 – 4.00 (m, 
2H), 3.04 (dd, J = 13.1, 7.5 Hz, 1H), 2.88 (dd, J = 13.1, 4.9 Hz, 1H), 2.16 (ddd, J = 13.7, 6.5, 3.2 
Hz, 1H), 1.81 (ddd, J = 13.3, 8.2, 3.8 Hz, 1H). 13C NMR (DMSO-d6) δ 150.6, 146.9, 142.8, 135.2, 
131.4, 129.0, 127.4, 125.6, 122.1, 116.8, 116.0, 113.1, 67.1, 62.7, 51.3, 32.5. HRMS (ESI) calcd 




Following general procedure C, sulfonamide 38 was obtained from aminoalcohol 30 (48 mg, 0.24 
mmol) and 5-bromothiophene-2-sulfonyl chloride (78 mg, 0.30 mmol) in 28% yield (29 mg) as a 
white solid. Reverse phase column chromatography: ACN/H2O, 5:95. 
1H NMR (400 MHz, CDCl3) 
δ 7.35 (d, J = 4.0 Hz, 1H), 7.08 (d, J = 4.0 Hz, 1H), 7.05 (dd, J = 9.0, 3.0 Hz, 1H), 6.92 (ddd, J = 
9.0, 7.8, 3.1 Hz, 1H), 6.79 (dd, J = 9.0, 4.7 Hz, 1H), 4.97 (br s, 1H, NH), 4.25-4.14 (m, 2H), 3.29 
(dd, J = 30.8, 13.0 Hz, 2H), 2.40 (ddd, J = 14.1, 5.9, 3.1 Hz, 1H), 2.03-1.96 (m, 2H).  13C NMR 
(101 MHz, CDCl3) δ 157.0 (d, J = 239.5 Hz), 150.7, 141.5, 132.4, 130.6, 126.0 (d, J = 6.1 Hz), 
120.3, 118.6 (d, J = 7.8 Hz), 117.3 (d, J = 23.2 Hz), 112.6 (d, J = 23.6 Hz), 68.6, 63.6, 51.6, 32.8. 
HRMS (ESI) calcd for [M-OH+H]+ C14H12BrFNO3S2 403.9426, found 403.9420. Spectra available 
at: https://doi.org/10.14469/hpc/6022 
3-Bromo-N-((6-fluoro-4-hydroxychroman-4-yl)methyl)benzenesulfonamide (39). Following 
general procedure C, sulfonamide 39 was obtained from aminoalcohol 30 (49 mg, 0.25 mmol) and 
3-bromobenzenesulfonyl chloride (76 mg, 0.30 mmol) in 35% yield (37 mg) as a pale-yellow solid. 
Reverse phase column chromatography: ACN/H2O, 5:95. 
1H NMR (400 MHz, CDCl3) δ 7.99 (t, 
J = 1.8 Hz, 1H), 7.77 (ddd, J = 7.9, 1.7, 1.0 Hz, 1H), 7.73 (ddd, J = 8.0, 1.9, 1.0 Hz, 1H), 7.41 (t, 
J = 7.9 Hz, 1H), 7.01 (dd, J = 9.0, 3.0 Hz, 1H), 6.91 (ddd, J = 9.0, 7.8, 3.1 Hz, 1H), 6.78 (dd, J = 
9.0, 4.7 Hz, 1H), 4.99 (s, 1H), 4.32 – 4.14 (m, 2H), 3.32 (dd, J = 13.2, 6.8 Hz, 1H), 3.19 (d, J = 
13.9 Hz, 1H), 2.43 (ddd, J = 14.0, 5.8, 3.1 Hz, 1H), 2.19 – 1.88 (m, 2H). 13C NMR (101 MHz, 
CDCl3) δ 157.0 (d, J = 239.3 Hz), 155.8, 150.6, 141.7, 136.1, 131.0, 129.9, 126.0 (d, J = 6.4 Hz), 
125.5, 123.4, 118.5 (d, J = 7.8 Hz), 117.1 (d, J = 23.3 Hz), 112.6 (d, J = 23.5 Hz), 68.7, 63.6, 51.4, 
32.6. HRMS (ESI) calcd for [M-OH+H]+ C16H14BrFNO3S 397.9862, found 397.9859. Spectra 
available at: https://doi.org/10.14469/hpc/6023 
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5-Bromo-N-((7-fluoro-4-hydroxychroman-4-yl)methyl)thiophene-2-sulfonamide (40). 
Following general procedure C, sulfonamide 40 was obtained from aminoalcohol 31 (35 mg, 0.2 
mmol) and 5-bromothiophene-2-sulfonyl chloride (52 mg, 0.2 mmol) in 53% yield (40 mg) as a 
yellow powder. Column chromatography: pentane/EtOAc, 2:1. 1H NMR (400 MHz, CDCl3) δ 7.34 
(d, J = 4.0 Hz, 1H), 7.31 (dd, J = 8.8, 6.4 Hz, 1H), 7.07 (d, J = 4.0 Hz, 1H), 6.63 (ddd, J = 8.6, 8.1, 
2.6 Hz, 1H), 6.54 (dd, J = 10.1, 2.6 Hz, 1H), 5.12 (t, J = 6.5 Hz, 1H, NH), 4.30 – 4.18 (m, 2H), 
3.38 – 3.25 (m, 2H), 2.37 (ddd, J = 14.1, 6.3, 3.4 Hz, 1H), 2.09 – 1.97 (m, 2H, OH, ½CH2). 
13C 
NMR (101 MHz, CDCl3) δ 163.6 (d, J = 247.4 Hz), 156.1 (d, J = 12.4 Hz), 141.7, 132.4, 130.6, 
127.9 (d, J = 10.1 Hz), 121.2 (d, J = 2.7 Hz), 120.3, 108.6 (d, J = 22.1 Hz), 104.5 (d, J = 24.3 Hz), 
68.2, 63.9, 51.7, 33.0. 19F NMR (377 MHz, CDCl3) δ -110.8 (dd, J = 16.3, 7.9 Hz). HRMS (ESI) 
calcd for [M-H]- C14H13BrFNO4S2 419.9375, found 419.9368. Spectra available at: 
https://doi.org/10.14469/hpc/5841 
3-Bromo-N-((7-fluoro-4-hydroxychroman-4-yl)methyl)benzenesulfonamide (41). Following 
general procedure C, sulfonamide 41 was obtained from aminoalcohol 31 (35 mg, 0.2 mmol) and 
3-bromobenzenesulfonyl chloride (51 mg, 0.2 mmol) in 53% yield (40 mg) as a white powder. 
Column chromatography: pentane/EtOAc, 2:1. 1H NMR (400 MHz, CDCl3) δ 7.98 (t, J = 1.8 Hz, 
1H), 7.76 (ddd, J = 7.8, 1.6, 1.0 Hz, 1H), 7.72 (ddd, J = 8.0, 1.9, 1.0 Hz, 1H), 7.40 (t, J = 7.9 Hz, 
1H), 7.28 (dd, J = 8.6, 6.3 Hz, 1H), 6.61 (ddd, J = 8.7, 8.0, 2.6 Hz, 1H), 6.53 (dd, J = 10.1, 2.6 Hz, 
1H), 5.10 (dd, J = 8.2, 4.7 Hz, 1H, NH), 4.32 – 4.17 (m, 2H), 3.32 – 3.21 (m, 2H), 2.37 (ddd, J = 
14.1, 6.2, 3.3 Hz, 1H), 2.14 (br s, 1H, OH), 2.06 – 1.95 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 
163.6 (d, J = 247.8 Hz), 156.1 (d, J = 12.4 Hz), 142.0, 136.1, 130.9, 130.0, 127.9 (d, J = 10.1 Hz), 
125.6, 123.4, 121.2 (d, J = 3.0 Hz), 108.5 (d, J = 22.2 Hz), 104.4 (d, J = 24.5 Hz), 68.3, 63.9, 51.5, 
32.9. 19F NMR (377 MHz, CDCl3) δ -110.93 (dd, J = 16.3, 7.9 Hz). HRMS (ESI) calcd for [M-H]
- 
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C16H15BrFNO4S 413.9811, found 413.9820. Spectra available at: 
https://doi.org/10.14469/hpc/5842 
Chiral resolution was performed on a Chiralpack® IE-3 column using an isocratic gradient of 
hexane/isopropanol, 7:3 to yield (-)-41 and (+)-41. 
(+)-41: [D
20 = + 74° (c = 0.49, CDCl3) 
(-)-41:D
20 = - 82° (c = 0.41, CDCl3) 
5-Bromo-N-((4-hydroxy-8-methoxychroman-4-yl)methyl)thiophene-2-sulfonamide (42). 
Following general procedure C, sulfonamide 42 was obtained from aminoalcohol 32 (60 mg, 0.3 
mmol) and 5-bromothiophene-2-sulfonyl chloride (84 mg, 0.3 mmol) in 67% yield (86 mg) as a 
yellow powder. Column chromatography: hexane/EtOAc, 1:1. 1H NMR (400 MHz, CDCl3) δ 7.34 
(d, J = 4.0 Hz, 1H), 7.06 (d, J = 4.0 Hz, 1H), 6.95 (dd, J = 7.8, 1.7 Hz, 1H), 6.89 (t, J = 7.9 Hz, 
1H), 6.83 (dd, J = 7.9, 1.7 Hz, 1H), 4.93 (dd, J = 7.2, 5.8 Hz, 1H, NH), 4.41 – 4.26 (m, 2H), 3.87 
(s, 3H), 3.43 – 3.30 (m, 2H), 2.39 (ddd, J = 14.1, 6.6, 3.8 Hz, 1H), 2.10 – 1.98 (m, 2H, OH, ½CH2). 
13C NMR (101 MHz, Chloroform-d) δ 148.6, 144.4, 141.6, 132.4, 130.6, 125.5, 120.7, 120.2, 
117.7, 111.5, 68.3, 63.8, 56.1, 51.7, 32.9. HRMS (ESI) calcd for [M-H]- C15H16BrNO5S2 431.9575, 
found 431.9583. Spectra available at: https://doi.org/10.14469/hpc/5843 
3-Bromo-N-((4-hydroxy-8-methoxychroman-4-yl)methyl)benzenesulfonamide (43). 
Following general procedure C, sulfonamide 43 was obtained from aminoalcohol 32 (60 mg, 0.3 
mmol) and 3-bromobenzenesulfonyl chloride (82 mg, 0.3 mmol) in 69% yield (86 mg) as a white 
powder. Column chromatography: hexane/EtOAc, 1:2. 1H NMR (400 MHz, CDCl3) δ 7.99 (t, J = 
1.8 Hz, 1H), 7.77 (ddd, J = 7.8, 1.7, 1.0 Hz, 1H), 7.71 (ddd, J = 8.0, 1.9, 1.0 Hz, 1H), 7.40 (t, J = 
7.9 Hz, 1H), 6.91 (dd, J = 7.8, 2.0 Hz, 1H), 6.87 (t, J = 7.8 Hz, 1H), 6.82 (dd, J = 7.7, 1.9 Hz, 1H), 
 49 
4.85 (dd, J = 7.2, 5.5 Hz, 1H, NH), 4.44 – 4.23 (m, 2H), 3.87 (s, 3H), 3.39 – 3.19 (m, 2H), 2.39 
(ddd, J = 14.1, 6.6, 3.7 Hz, 1H), 2.04 (ddd, J = 14.0, 7.8, 4.3 Hz, 1H), 1.98 (s, 1H, OH). 13C NMR 
(101 MHz, Chloroform-d) δ 148.6, 144.4, 141.9, 136.0, 130.9, 130.0, 125.62, 125.56, 123.3, 120.7, 
117.7, 111.5, 68.4, 63.8, 56.1, 51.5, 32.9. HRMS (ESI) calcd for [M-H]- C17H18BrNO5S 426.0011, 
found 426.0011. Spectra available at: https://doi.org/10.14469/hpc/5844 
5-Bromo-N-((4-hydroxy-2-phenylchroman-4-yl)methyl)thiophene-2-sulfonamide (44). 
Following general procedure C, sulfonamide 44 was obtained from aminoalcohol 33 (18 mg, 0.07 
mmol) and 5-bromothiophene-2-sulfonyl chloride (20 mg, 0.08 mmol) in 28% yield (9.6 mg) as 
an off-white solid. Column chromatography: DCM/1% NH4OH in MeOH, 98:2. 
1H NMR (400 
MHz, CDCl3) δ 7.52 – 7.48 (m, 2H), 7.44 – 7.40 (m, 3H), 7.37 – 7.33 (m, 2H), 7.27 – 7.23 (m, 
1H), 7.05 (d, J = 4.0 Hz, 1H), 6.97 (td, J = 7.5, 1.1 Hz, 1H), 6.93 (dd, J = 8.3, 1.0 Hz, 1H), 5.23 
(dd, J = 12.2, 1.8 Hz, 1H), 5.19 (br s, 1H, NH), 3.58 (d, J = 13.4 Hz, 1H), 3.30 (dd, J = 13.4, 1.6 
Hz, 1H), 2.81 (dd, J = 13.7, 2.1 Hz, 1H), 2.02 (ddd, J = 13.8, 12.4, 1.7 Hz, 1H), 1.87 (br s, 1H, 
OH). 13C NMR (101 MHz, CDCl3) δ 154.6, 142.0, 140.3, 132.3, 130.6, 130.3, 128.8, 128.4, 126.5, 
126.1, 125.6, 121.2, 120.1, 117.4, 76.3, 70.3, 51.8, 40.3. HRMS (ESI) calcd for [M-H]- 
C20H17NO4S2Br 477.9782, found 477.9777. Spectra available at: 
https://doi.org/10.14469/hpc/5847 
3-Bromo-N-((4-hydroxy-2-phenylchroman-4-yl)methyl)benzenesulfonamide (45). Following 
general procedure C, sulfonamide 45 was obtained from aminoalcohol 33 (15 mg, 0.060 mmol) 
and 3-bromobenzenesulfonyl chloride (16 mg, 0.064 mmol) in 12% yield (3.3 mg) as a pale yellow 
solid. Column chromatography: DCM/1% NH4OH in MeOH, 98:2. 
1H NMR (400 MHz, CDCl3) 
δ 8.02 (t, J = 1.8 Hz, 1H), 7.79 (ddd, J = 7.8, 1.7, 1.0 Hz, 1H), 7.70 (ddd, J = 8.0, 1.9, 1.0 Hz, 1H), 
7.52 – 7.49 (m, 2H), 7.44 – 7.31 (m, 5H), 7.26 – 7.21 (m, 1H), 6.98 – 6.92 (m, 2H), 5.25 (dd, J = 
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12.2, 1.7 Hz, 1H), 5.12 (br s, 1H, NH), 3.59 – 3.54 (m, 1H), 3.22 (d, J = 12.7 Hz, 1H), 2.84 (dd, J 
= 13.7, 2.1 Hz, 1H), 2.01 (ddd, J = 13.9, 12.5, 1.7 Hz, 1H), 1.85 (br s, 1H, OH). 13C NMR (101 
MHz, CDCl3) δ 154.6, 142.3, 140.4, 136.0, 130.9, 130.3, 129.9, 128.8, 128.3, 126.5, 126.1, 125.6, 
125.5, 123.4, 121.2, 117.4, 76.3, 70.4, 51.6, 40.3. HRMS (ESI) calcd for [M-H]- C22H19NO4SBr 
472.0218, found 472.0224. Spectra available at: https://doi.org/10.14469/hpc/5846 
3-(2-Methoxyphenoxy)propanoic acid (46).19 A solution of 2-methoxyphenol (2.7 mL, 24 
mmol) in DMF (10 mL) was added dropwise to a suspension of NaH (60% suspension in mineral 
oil, 2.9 g, 72 mmol) in DMF (20 mL). After stirring for 1.5 hours, a solution of 3-bromopropionic 
acid (3.7 g, 24 mmol) in anhydrous DMF (10 mL) was added dropwise, and the solution was stirred 
at rt overnight. The reaction was quenched with MeOH, acidified with 1M HCl (pH~3), and 
extracted with EtOAc (3x). The combined organic phases were washed with 5% LiCl (2x) and 
brine, dried over MgSO4 and concentrated in vacuo. The crude was re-dissolved in EtOAc and 
extracted with sat. NaHCO3. The aqueous layer was acidified with 1M HCl (pH 1) and the resulting 
precipitate was collected by filtration, washed with H2O and dried to provide acid 46 as a white 
solid (824 mg, 17% yield), which was used in the next step without further purification. The 
spectroscopic data corresponds with those previously reported.19 1H NMR (400 MHz CDCl3) δ 
6.99 – 6.89 (m, 4H), 4.31 (t, J = 6.5 Hz, 2H), 3.85 (s, 3H), 2.91 (t, J = 6.5 Hz, 2H). 13C NMR (101 
MHz, CDCl3) δ 176.1, 150.0, 148.0, 122.3, 121.2, 114.8, 112.4, 64.8, 56.2, 34.5. HRMS (ESI) 
calcd for [M+H]+ C10H12O4 196.0736, found 196.0740. Spectra available at: 
https://doi.org/10.14469/hpc/5855 
1-(2-(2-Bromoethoxy)phenyl)ethanone (47). To a stirred suspension of 1-(2-
hydroxyphenyl)ethanone (0.5 mL, 4.2 mmol) and K2CO3 (1.16 g, 8.40 mmol) in ACN, 1,2-
dibromoethane (4.0 mL, 41.6 mmol) was added and the mixture heated at reflux overnight. Water 
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was added and the mixture extracted with EtOAc, dried over MgSO4, filtered and evaporated under 
reduced pressure. The crude was purified by flash chromatography (pentane/EtOAc, 100:0 to 95:5) 
to provide ketone 47 as a pale yellow solid (350 mg, 34% yield). The spectroscopic data correspond 
with those previously reported.30 1H NMR (400 MHz, CDCl3) δ 7.76 (dd, J = 7.7, 1.8 Hz, 1H), 
7.46 (ddd, J = 8.4, 7.4, 1.8 Hz, 1H), 7.04 (td, J = 7.7, 0.9 Hz, 1H), 6.91 (d, J = 8.3 Hz, 1H), 4.41 
(t app, J = 5.8 Hz, 2H), 3.72 (t app, J = 5.8 Hz, 2H), 2.69 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 
199.8, 157.4, 133.7, 130.8, 128.8, 121.7, 112.4, 68.4, 32.4, 29.0. HRMS (ESI) calcd for [M-H]- 
C10H12O2Br 243.0021, found 243.0031. Spectra available at: https://doi.org/10.14469/hpc/5856 
3,4-Dihydrobenzo[b]oxepin-5(2H)-one (48). A solution of ketone 47 (350 mg, 1.43 mmol) in the 
minimum amount of anhydrous THF was added dropwise to a suspension of NaH (60% in mineral 
oil, 115 mg, 2.87 mmol) in dry THF (3.6 mL) at 0 ºC, and the resulting mixture was allowed to 
stir at rt overnight. The mixture was cooled down to 0 ºC and water was carefully added until no 
reaction was observed. The mixture was diluted with water, neutralised with 2N HCl (aq.), 
extracted with EtOAc (2x), dried over MgSO4, filtered and evaporated under reduced pressure. 
The crude was purified by flash chromatography (pentane/EtOAc, 95:5 to 85:15) to provide ketone 
48 as a colourless oil (179 mg, 77% yield). The spectroscopic data correspond with those 
previously reported.31 1H NMR (400 MHz, CDCl3) δ 7.77 (dd, J = 7.8, 1.5 Hz, 1H), 7.45 – 7.41 
(m, 1H), 7.12 – 7.06 (m, 2H), 4.24 (t, J = 6.6 Hz, 2H), 2.90 (t, J = 6.9 Hz, 2H), 2.22 (p, J = 6.7 Hz, 
2H). 13C NMR (101 MHz, CDCl3) δ 200.9, 162.2, 133.9, 129.7, 129.3, 123.0, 121.0, 73.0, 40.8, 
26.6. HRMS (ESI) calcd for [M+H]+ C10H11O2 163.0759, found 163.0751. Spectra available at: 
https://doi.org/10.14469/hpc/5857 
5-((Trimethylsilyl)oxy)-2,3,4,5-tetrahydrobenzo[b]oxepine-5-carbonitrile (49). Following 
general procedure A, cyanohydrin 49 was obtained from ketone 48 (150 mg, 0.92 mmol) in 97% 
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yield (145 mg) as a white solid. Column chromatography: pentane to pentane/EtOAc, 98:2. 1H 
NMR (400 MHz, CDCl3) δ 7.62 (dd, J = 7.8, 1.7 Hz, 1H), 7.29 (td, J = 7.6, 1.6 Hz, 1H), 7.14 (td, 
J = 7.6, 1.3 Hz, 1H), 7.04 (dd, J = 7.9, 1.2 Hz, 1H), 4.19 (ddd, J = 9.7, 5.4, 3.6 Hz, 1H), 3.85 (ddd, 
J = 11.8, 8.7, 2.7 Hz, 1H), 2.32 – 2.12 (m, 4H), 0.22 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 158.2, 
133.2, 130.6, 127.4, 124.0, 122.9, 120.5, 73.7, 72.6, 40.2, 26.9, 1.2. HRMS (ESI) calcd for 
[M+ACN+Na]+ C16H22N2O2SiNa 325.1348, found 325.1340. Spectra available at: 
https://doi.org/10.14469/hpc/5858 
5-(Aminomethyl)-2,3,4,5-tetrahydrobenzo[b]oxepin-5-ol (50). Following general procedure B, 
aminoalcohol 50 was obtained from cyanohydrin 49 (200 mg, 0.76 mmol) in 35% yield (52 mg). 
Column chromatography: 0-10% of EtOAc/EtOH 3:1 in pentane. 1H NMR (400 MHz, CDCl3) δ 
7.63 (dd, J = 7.7, 1.8 Hz, 1H), 7.18 (td, J = 7.6, 1.8 Hz, 1H), 7.10 (td, J = 7.5, 1.4 Hz, 1H), 6.97 
(dd, J = 7.8, 1.4 Hz, 1H), 4.38 (dtd, J = 12.0, 3.7, 1.3 Hz, 1H), 3.58 (td, J = 11.9, 1.9 Hz, 1H), 3.38 
(d, J = 12.2 Hz, 1H), 2.85 (d, J = 12.2 Hz, 1H), 2.22- 2.10 (m, 1H), 2.09 – 2.03 (m, 1H), 1.95 (dd, 
J = 13.4, 3.7 Hz, 1H), 1.82 – 1.75 (m, 1H). 13C NMR (101 MHz, CDCl3/MeOD, 9:1) δ 157.0, 
137.6, 128.6, 127.4, 123.9, 122.1, 75.6, 73.0, 47.7, 37.1, 26.5. HRMS (ESI) calcd for [M+H]+ 
C11H16NO2 194.1181, found 194.1185. Spectra available at: https://doi.org/10.14469/hpc/5859 
5-Bromo-N-((5-hydroxy-2,3,4,5-tetrahydrobenzo[b]oxepin-5-yl)methyl)thiophene-2-
sulfonamide (51). Following general procedure C, sulfonamide 51 was obtained from 
aminoalcohol 50 (25 mg, 0.13 mmol) and 5-bromothiophene-2-sulfonyl chloride (37 mg, 0.14 
mmol) in 63% yield (34 mg) as a yellow solid. Column chromatography: 15-30% EtOAc/EtOH 
3:1 in pentane. 1H NMR (400 MHz, CDCl3) δ 7.52 (dd, J = 7.8, 1.7 Hz, 1H), 7.25 (d, J = 4.0 Hz, 
1H), 7.22 (td, J = 7.6, 1.7 Hz, 1H), 7.11 (td, J = 7.6, 1.3 Hz, 1H), 6.99 (d, J = 4.0 Hz, 1H), 6.95 
(dd, J = 7.9, 1.2 Hz, 1H), 5.00 (dd, J = 7.7, 4.8 Hz, 1H, NH), 4.31 (ddd, J = 11.3, 3.8, 2.7 Hz, 1H), 
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3.67 – 3.60 (m, 2H), 3.31 (dd, J = 12.5, 4.7 Hz, 1H), 2.65 (s, 1H, OH), 2.27 – 2.15 (m, 2H), 1.89 
– 1.81 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 157.3, 141.2, 136.7, 132.5, 130.5, 129.4, 126.8, 
124.5, 122.6, 120.2, 75.8, 73.1, 49.5, 37.0, 26.5. HRMS (ESI) calcd for [M-H]- C15H15BrNO4S2 
415.9626, found 415.9634. Spectra available at: https://doi.org/10.14469/hpc/5860 
3-Bromo-N-((5-hydroxy-2,3,4,5-tetrahydrobenzo[b]oxepin-5-yl)methyl)benzene-
sulfonamide (52). Following general procedure C, sulfonamide 52 was obtained from 
aminoalcohol 50 (25 mg, 0.13 mmol) and 3-bromobenzenesulfonyl chloride (36 mg, 0.14 mmol) 
in 38% yield (20 mg) as a white solid. Column chromatography: 15-30% EtOAc/EtOH 3:1 in 
pentane. 1H NMR (400 MHz, CDCl3) δ 7.91 (t, J = 1.8 Hz, 1H), 7.69 (ddd, J = 7.9, 1.5, 1.0 Hz, 
1H), 7.66 (ddd, J = 8.0, 1.8, 1.0 Hz, 1H), 7.51 (dd, J = 7.8, 1.7 Hz, 1H), 7.33 (t, J = 7.9 Hz, 1H), 
7.20 (td, J = 7.6, 1.7 Hz, 1H), 7.10 (td, J = 7.6, 1.3 Hz, 1H), 6.94 (dd, J = 7.8, 1.2 Hz, 1H), 4.85 
(dd, J = 8.1, 4.7 Hz, 1H, NH), 4.33 – 4.29 (m, 1H), 3.66 – 3.58 (m, 2H), 3.23 (dd, J = 12.6, 4.7 
Hz, 1H), 2.61 (s, 1H, OH), 2.25 – 2.16 (m, 2H), 1.88 – 1.81 (m, 2H). 13C NMR (101 MHz, CDCl3) 
δ 157.2, 141.5, 136.7, 135.9, 130.8, 130.0, 129.5 126.8, 125.7, 124.4, 123.3, 122.6, 75.9, 73.1, 
49.3, 37.0, 26.5. HRMS (ESI) calcd for [M-H]- C17H17BrNO4S 410.0062, found 410.0055. Spectra 
available at: https://doi.org/10.14469/hpc/5861 
3-(Aminomethyl)-2,3-dihydrobenzofuran-3-ol (53). To a flask containing benzofuran-3(2H)-
one (500 mg, 3.73 mmol) and potassium phthalimide (17 mg, 0.09 mmol), trimethylsylilcyanide 
(0.60 mL, 4.47 mmol) was added, and the resulting mixture was stirred at rt overnight. Water was 
then added, and the mixture extracted with EtOAc (2x), dried over MgSO4, filtered and evaporated 
under reduced pressure to yield the intermediate cyanohydrin, which due to stability issues was 
directly submitted to general procedure B to provide aminoalcohol 53 in 35% yield over two steps 
(202 mg). 1H NMR (400 MHz, CDCl3) δ 7.32 (dd, J = 7.5, 0.8 Hz, 1H), 7.27 – 7.23 (m, 1H), 6.94 
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(td, J = 7.4, 0.7 Hz, 1H), 6.86 (d, J = 8.1 Hz, 1H), 4.43 (s, 2H), 3.13 (d, J = 12.9 Hz, 1H), 3.04 (d, 
J = 12.9 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 160.5, 130.6, 129.8, 123.7, 121.1, 110.8, 81.2, 
80.3, 49.3. HRMS (ESI) calcd for [M+H]+ C9H12NO2 166.0868, found 166.0866. Spectra available 
at: https://doi.org/10.14469/hpc/5862 
5-Bromo-N-((3-hydroxy-2,3-dihydrobenzofuran-3-yl)methyl)thiophene-2-sulfonamide (54). 
Following general procedure C, sulfonamide 54 was obtained from aminoalcohol 53 (50 mg, 0.30 
mmol) and 5-bromothiophene-2-sulfonyl chloride (86 mg, 0.33 mmol) in 50% yield (60 mg) as a 
yellow solid. Column chromatography: 5-10% EtOAc/EtOH 3:1 in pentane. 1H NMR (400 MHz, 
CDCl3) δ 7.37 (d, J = 4.0 Hz, 1H), 7.32 – 7.28 (m, 2H), 7.09 (d, J = 4.0 Hz, 1H), 6.95 (td, J = 7.5, 
0.8 Hz, 1H), 6.88 (dd, J = 8.7, 0.9 Hz, 1H), 5.02 (t, J = 6.0 Hz, 1H, NH), 4.57 (d, J = 10.7 Hz, 1H), 
4.42 (d, J = 10.6 Hz, 1H), 3.47 (dd, J = 12.6, 5.1 Hz, 1H), 3.37 (dd, J = 12.7, 7.2 Hz, 1H), 2.31 (s, 
1H, OH). 13C NMR (101 MHz, CDCl3) δ 160.5, 141.2, 132.7, 131.6, 130.7, 127.8, 123.8, 121.4, 
120.5, 111.2, 81.1, 79.7, 50.1. HRMS (ESI) calcd for [M-H]- C13H11BrNO4S2 387.9313, found 
387.9320. Spectra available at: https://doi.org/10.14469/hpc/5863 
3-Bromo-N-((3-hydroxy-2,3-dihydrobenzofuran-3-yl)methyl)benzenesulfonamide (55). 
Following general procedure C, sulfonamide 55 was obtained from aminoalcohol 53 (50 mg, 0.30 
mmol) and 3-bromobenzenesulfonyl chloride (84 mg, 0.33 mmol) in 52% yield (60 mg) as a white 
solid. Column chromatography: 5-10% EtOAc/EtOH 3:1 in pentane. 1H NMR (400 MHz, CDCl3) 
δ 8.00 (t, J = 1.8 Hz, 1H), 7.78 (ddd, J = 7.9, 1.5, 0.9 Hz, 1H), 7.73 (ddd, J = 8.0, 1.7, 0.9 Hz, 1H), 
7.42 (t, J = 7.9 Hz, 1H), 7.31 – 7.27 (m, 2H), 6.93 (td, J = 7.6, 0.6 Hz, 1H), 6.87 (d, J = 8.4 Hz, 
1H), 5.00 (br s, 1H, NH), 4.55 (d, J = 10.7 Hz, 1H), 4.40 (d, J = 10.7 Hz, 1H), 3.39 (dd, J = 12.5, 
3.5 Hz, 1H), 3.31 (dd, J = 12.5, 6.4 Hz, 1H), 2.36 (s, 1H, OH). 13C NMR (101 MHz, CDCl3) δ 
160.5, 141.5, 136.2, 131.6, 130.9, 130.1, 127.9, 125.7, 123.8, 123.4, 121.4, 111.2, 81.1, 79.8, 50.0. 
 55 
HRMS (ESI) calcd for [M-H]- C15H13BrNO4S 381.9749, found 381.9753. Spectra available at: 
https://doi.org/10.14469/hpc/5864 
1-((Trimethylsilyl)oxy)-1,2,3,4-tetrahydronaphthalene-1-carbonitrile (56). Following general 
procedure A, cyanohydrin 56 was obtained from 3,4-dihydronaphthalen-1(2H)-one (200 mg, 1.37 
mmol) in quantitative yield (335 mg), and was used in the next step without further purification. 
1H NMR (400 MHz, CDCl3) δ 7.67 – 7.63 (m, 1H), 7.29 – 7.24 (m, 2H), 7.13 – 7.10 (m, 1H), 2.89 
– 2.77 (m, 2H), 2.34 (ddd, J = 12.9, 8.3, 3.3 Hz, 1H), 2.20 (ddd, J = 12.5, 9.2, 3.3 Hz, 1H), 2.11 – 
1.92 (m, 2H), 0.21 (s, 9H). Spectra available at: https://doi.org/10.14469/hpc/5865 
4-((Trimethylsilyl)oxy) thiochromane-4-carbonitrile (57). Following general procedure A, 
cyanohydrin 57 was obtained from thiochroman-4-one (200 mg, 1.22 mmol) in 45% yield (145 
mg) as a pale-yellow oil, which and was used in the next step without further purification. 1H NMR 
(400 MHz, CDCl3) δ 7.71 (dd, J = 8.1, 1.4 Hz, 1H), 7.25 – 7.21 (m, 1H), 7.15 – 7.11 (m, 2H), 3.32 
(ddd, J = 12.8, 11.3, 3.3 Hz, 1H), 3.02 (ddd, J = 12.8, 6.1, 3.6 Hz, 1H), 2.64 (ddd, J = 13.4, 6.1, 
3.3 Hz, 1H), 2.36 (ddd, J = 13.5, 11.3, 3.6 Hz, 1H), 0.11 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 
133.3, 130.8, 130.0, 129.4, 127.1, 124.4, 121.2, 68.9, 36.0, 21.1, 1.1. Spectra available at: 
https://doi.org/10.14469/hpc/5866 
1-(Aminomethyl)-1,2,3,4-tetrahydronaphthalen-1-ol (58). Following general procedure B, 
aminoalcohol 58 was obtained from cyanohydrin 56 (300 mg, 1.2 mmol) in 91% yield (195 mg) 
as a colourless oil. Column chromatography: DCM/1% NH4OH in MeOH, 10:0 to 9:1. 
1H NMR 
(400 MHz, CDCl3) δ 7.52 – 7.50 (m, 1H), 7.22 – 7.16 (m, 2H), 7.09 – 7.07 (m, 1H), 2.98, 2.97 
(ABq, J = 13.4 Hz, 2H), 2.87 – 2.72 (m, 5H, OH, NH2, CH2), 2.08 – 2.03 (m, 1H), 1.93 – 1.72 (m, 
3H). 13C NMR (101 MHz, CDCl3) δ 139.6, 137.3, 129.1, 127.8, 126.5, 126.4, 71.2, 49.6, 33.6, 
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29.5, 19.9. HRMS (ESI) calcd for [M+H]+ C11H16NO 178.1232, found 178.1237. Spectra available 
at: https://doi.org/10.14469/hpc/5867 
4-(Aminomethyl)thiochroman-4-ol (59). Following general procedure B, aminoalcohol 59 was 
obtained from cyanohydrin 57 (130 mg, 0.55 mmol) in 70% yield (70 mg) as a white solid. Column 
chromatography: EtOAc/1% NH4OH in MeOH, 99:1 to 95:5. 
1H NMR (400 MHz, CDCl3) δ 7.58 
– 7.56 (m, 1H), 7.12 – 7.06 (m, 3H), 3.10 (dd, J = 12.1, 4.1 Hz, 1H), 3.03 (dt, J = 12.6, 4.8 Hz, 
1H), 2.92, 2.96 (ABq, J = 12.9 Hz, 2H), 2.30 (ddd, J = 13.5, 5.0, 4.1 Hz, 1H), 2.22 – 2.10 (m, 2H, 
OH, ½CH2).
 13C NMR (101 MHz, CDCl3) δ 138.2, 133.2, 127.7, 126.43, 126.37, 124.3, 70.6, 49.2, 
33.2, 23.4. HRMS (ESI) calcd for [M+H]+ C10H14NOS 196.0796, found 196.0798. Spectra 
available at: https://doi.org/10.14469/hpc/5868 
5-Bromo-N-((1-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)methyl)thiophene-2-
sulfonamide (60). Following general procedure C, sulfonamide 60 was obtained from 
aminoalcohol 58 (30 mg, 0.17 mmol) and 5-bromothiophene-2-sulfonyl chloride (49 mg, 0.19 
mmol) in 39% yield (27 mg) as a yellow solid. Column chromatography: 5-10% EtOAc/EtOH 3:1 
in pentane. 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.43 (m, 1H), 7.31 (d, J = 3.9 Hz, 1H), 7.23 – 
7.17 (m, 2H), 7.11 – 7.09 (m, 1H), 7.04 (d, J = 3.9 Hz, 1H), 5.17 (dd, J = 8.3, 3.7 Hz, 1H, NH), 
3.30 (dd, J = 12.7, 8.8 Hz, 1H), 3.17 (dd, J = 12.7, 4.0 Hz, 1H), 2.87 – 2.73 (m, 2H), 2.36 – 2.31 
(m, 1H), 2.05 (br s, 1H, OH), 1.90 – 1.74 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 141.9, 139.3, 
137.5, 132.2, 130.5, 129.3, 128.2, 126.6, 126.4, 119.9, 72.4, 52.0, 34.2, 29.5, 20.1. HRMS (ESI) 
calcd for [M-H]- C15H15BrNO3S2 399.9677, found 399.9669. Spectra available at: 
https://doi.org/10.14469/hpc/5869 
3-Bromo-N-((1-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)methyl) benzenesulfonamide 
(61). Following general procedure C, sulfonamide 61 was obtained from aminoalcohol 58 (30 mg, 
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0.17 mmol) and 3-bromobenzenesulfonyl chloride (47 mg, 0.19 mmol) in 75% yield (50 mg) as a 
white solid. Column chromatography: 5-10% EtOAc/EtOH 3:1 in pentane. 1H NMR (400 MHz, 
CDCl3) δ 7.98 (app s, 1H), 7.76 (d, J = 7.8 Hz, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.41 (d, J = 7.8 Hz, 
1H), 7.37 (d, J = 7.9 Hz, 1H), 7.22 – 7.16 (m, 2H), 7.11 – 7.08 (m, 1H), 5.02 (dd, J = 8.5, 3.7 Hz, 
1H, NH), 3.27 (dd, J = 12.8, 8.8 Hz, 1H), 3.10 (dd, J = 12.8, 4.0 Hz, 1H), 2.86 – 2.73 (m, 2H), 
2.36 – 2.31 (m, 1H), 1.95 (br s, 1H, OH), 1.91 – 1.69 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 
142.1, 139.4, 137.6, 135.8, 130.8, 130.0, 129.3, 128.2, 126.6, 126.3, 125.6, 123.3, 72.4, 51.8, 34.2, 
29.5, 20.1. HRMS (ESI) calcd for [M-H]- C17H17BrNO3S 394.0113, found 394.0120. Spectra 
available at: https://doi.org/10.14469/hpc/5870 
5-Bromo-N-((4-hydroxythiochroman-4-yl)methyl)thiophene-2-sulfonamide (62). Following 
general procedure C, sulfonamide 62 was obtained from aminoalcohol 59 (30 mg, 0.15 mmol) and 
5-bromothiophene-2-sulfonyl chloride (44 mg, 0.17 mmol) in 43% yield (27 mg) as a yellow solid. 
Column chromatography: pentane/EtOAc, 7:3 to 1:1. 1H NMR (400 MHz, CDCl3) δ 7.51 (dd, J = 
7.7, 1.0 Hz, 1H), 7.31 (d, J = 4.0 Hz, 1H), 7.17 – 7.05 (m, 3H), 7.03 (d, J = 4.0 Hz, 1H), 5.06 (dd, 
J = 8.7, 3.2 Hz, 1H, NH), 3.40 (dd, J = 13.0, 9.1 Hz, 1H), 3.20 (td, J = 12.7, 3.7 Hz, 1H), 3.10 (dd, 
J = 13.0, 3.5 Hz, 1H), 2.98 (dt, J = 13.1, 4.6 Hz, 1H), 2.62 (ddd, J = 13.4, 4.7, 3.9 Hz, 1H), 2.12 
(br s, 1H, OH), 2.03 (td, J = 12.7, 4.0 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 141.4, 136.4, 133.6, 
132.4, 130.6, 128.6, 126.7, 126.3, 124.7, 120.2, 71.6, 50.3, 32.7, 23.1. HRMS (ESI) calcd for [M-
H]- C14H13BrNO3S3 417.9241, found 417.9250. Spectra available at: 
https://doi.org/10.14469/hpc/5871 
3-Bromo-N-((4-hydroxythiochroman-4-yl)methyl)benzenesulfonamide (63). Following 
general procedure C, sulfonamide 63 was obtained from aminoalcohol 59 (30 mg, 0.15 mmol) and 
3-bromobenzenesulfonyl chloride (42 mg, 0.17 mmol) in 33% yield (23 mg) as a white solid. 
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Column chromatography: pentane/EtOAc, 7:3 to 1:1. 1H NMR (400 MHz, CDCl3) δ 7.96 (t, J = 
1.8 Hz, 1H), 7.74 (ddd, J = 7.8, 1.5, 1.0 Hz, 1H), 7.69 (ddd, J = 8.0, 1.8, 0.9 Hz, 1H), 7.48 (dd, J 
= 7.8, 1.1 Hz, 1H), 7.37 (t, J = 7.9 Hz, 1H), 7.21 – 6.94 (m, 3H), 5.03 (dd, J = 8.5, 3.0 Hz, 1H, 
NH), 3.37 (dd, J = 13.1, 9.1 Hz, 1H), 3.21 (td, J = 12.7, 3.7 Hz, 1H), 3.07 – 2.92 (m, 2H), 2.63 
(ddd, J = 13.4, 4.8, 3.8 Hz, 1H), 2.14 (s, 1H, OH), 2.02 (td, J = 12.6, 4.1 Hz, 1H). 13C NMR (101 
MHz, CDCl3) δ 141.7, 136.4, 136.0, 133.6, 130.9, 130.0, 128.6, 126.6, 126.3, 125.6, 124.6, 123.4, 
71.6, 50.2, 32.6, 23.1. HRMS (ESI) calcd for [M-H]- C16H15BrNO3S2 411.9677, found 411.9683. 
Spectra available at: https://doi.org/10.14469/hpc/5872 
N-((2H-Chromen-4-yl)methyl)-5-bromothiophene-2-sulfonamide (64). Borontrifluoride 
diethyletherate (0.05 mL, 0.4 mmol) was dissolved in dry DCM (1 mL) and added to a stirred 
solution of compound 3 (40 mg, 0.1 mmol) in dry DCM (1 mL) under N2 at 0 °C. The reaction 
mixture was stirred for 1h at 0 °C. Sat. NaHCO3 (aq.) was added and the mixture was diluted with 
DCM. The organic layer was separated and the aqueous layer was extracted with DCM (3x). The 
combined organic fractions were then washed with brine, dried and concentrated in vacuo. The 
crude product was purified by preparative HPLC (H2O:ACN 50:50 to 2:98, 30 min) to give 64 as 
a white solid (4.3 mg, 0.011 mmol, 11%). 1H NMR (400 MHz, MeOD) δ 7.37 (d, J = 4.0 Hz, 1H), 
7.18 (dd, J = 7.7, 1.5 Hz, 1H), 7.15 (d, J = 4.0 Hz, 1H), 7.11 (td, J = 7.8, 1.5 Hz, 1H), 6.87 (td, J 
= 7.6, 1.2 Hz, 1H), 6.73 (dd, J = 8.1, 1.0 Hz, 1H), 5.79 (t, J = 3.7 Hz, 1H), 4.68 (dt, J = 3.5, 1.3 
Hz, 2H), 3.94 (dd, J = 2.7, 1.3 Hz, 2H). 13C NMR (101 MHz, MeOD) δ 155.6, 133.3, 131.9, 130.8, 
130.3, 124.4, 122.33, 122.26, 120.0, 116.9, 66.1, 44.9 (two signals missing due to low quantity). 
HRMS (ESI) calcd for [M-H]- C14H11NO3S2Br 383.9364, found 383.9364. Spectra available at: 
https://doi.org/10.14469/hpc/5873 
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4-(Methoxymethylene)chromane (65).32 To a stirred suspension of 
(methoxymethyl)triphenylphosphonium chloride (5.2 g, 15 mmol) in anhydrous THF (100 mL) at 
– 78, nBuLi (2.5 M in toluene, 6.1 mL) was added dropwise. The resulting red mixture was allowed 
to stir at -78 ºC for 30 min and at rt for additional 30 min. The mixture was cooled down to -78ºC 
before a solution of 4-chromanone (1.5 g, 10 mmol) in anhydrous THF (20 mL) was slowly added. 
The mixture was stirred at that temperature for 30 min and then allowed to warm up to rt and 
stirred overnight. The reaction mixture was poured into water, extracted with EtOAc (3x), dried 
over MgSO4, filtered and evaporated under reduced pressure. The crude was purified by flash 
chromatography (pentane/EtOAc, 99:1) to provide alkene 65 in 86% yield (1.5 g) as a colourless 
oil containing a mixture of the Z/E isomers which were not assigned. 1H NMR (400 MHz, CDCl3, 
isomer 1(1)/isomer 2 (2), 3:1) δ 8.09 (dd, J = 7.9, 1.6 Hz, 1H1), 7.34 – 7.32 (m, 1H2), 7.11 – 7.02 
(m, 1H1, 1H2), 6.90 (ddd, J = 8.0, 7.3, 1.3 Hz, 1H1), 6.86 – 6.81 (m, 3H, 1H1, 2H2), 6.65 (t, J = 1.6 
Hz, 1H2), 6.03 (t, J = 1.2 Hz, 1H1), 4.23 – 4.21 (m, 2H1), 4.18 – 4.15 (m, 1H2), 3.76 (s, 3H1), 3.74 
(s, 3H2), 2.69 – 2.66 (m, 1H2), 2.48 – 2.45 (m, 2H1). 
13C NMR (101 MHz, CDCl3) δ 153.61 (2), 
153.56 (1), 143.8 (1), 141.2 (2), 128.9 (1), 127.6 (1), 127.1 (2), 121.9 (2), 121.4 (2), 120.9 (2), 
120.5 (1), 117.6 (2), 116.6 (1), 109.1 (2), 106.0 (1), 67.2 (1), 66.0 (2), 60.6 (1), 60.3 (2), 28.1 (1), 
23.0 (2). HRMS (FTMS) calcd for [M+H]+ C11H13O2 177.0910, found 177.0909. Spectra available 
at: https://doi.org/10.14469/hpc/5880 
Chromane-4-carbaldehyde (66). To a stirred solution of methyl ether 65 (760 mg, 4.31 mmol) 
in Et2O (15 mL) at 0 ºC, perchloric acid (70% in water, 4.74 mL) was added dropwise and the 
mixture was allowed to stir at rt for 45 min. The reaction mixture was quenched with sat. NaHCO3 
(43 mL), and the mixture was extracted with Et2O (2x), dried over MgSO4, filtered and evaporated 
under reduced pressure to afford aldehyde 66 in quantitative yield (699 mg) as a colourless oil 
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which was used straight away due to instability issues. 1H NMR (400 MHz, CDCl3) δ 9.74 (br s, 
1H), 7.23 – 7.19 (m, 2H), 6.97 (td, J = 7.6, 1.1 Hz, 1H), 6.89 (br d, J = 8.2 Hz, 1H), 4.24 (dddd, J 
= 11.2, 4.8, 3.6, 0.9 Hz, 1H), 4.00 (ddd, J = 11.2, 10.1, 2.6 Hz, 1H), 3.61 (t, J = 5.1 Hz, 1H), 2.44 
(dddd, J = 14.0, 4.9, 4.5, 2.7 Hz, 1H), 2.10 (tddd, J = 10.6, 6.3, 3.6, 0.7 Hz, 1H). Spectra available 
at: https://doi.org/10.14469/hpc/5881 
Chroman-4-ylmethanamine (67). Aldehyde 66 (699 mg, 4.31 mmol) and hydroxylamine 
hydrochloride salt (360 mg, 5.17 mmol) were dissolved in EtOH (3 mL) and stirred at rt for 45 
min. HCl (1.5 mL, 17.2 mmol) was added dropwise followed by zinc (705 mg, 10.8 mmol), which 
was added portionwise. The mixture was stirred for 15 min and then carefully quenched using 
ammonium hydroxide (30% in water, 1.3 mL) and 8M NaOH (2 mL). The reaction mixture was 
extracted with DCM (2x). The combined organic layers were extracted with 1M HCl and the 
organic layer was discarded. The aqueous layer was basified with 8M NaOH and extracted with 
Et2O (2x). The combined organic layers were dried over MgSO4, filtered and evaporated under 
reduced pressure to provide amine 67 in 33% yield (229 mg) as a pale-yellow oil which was used 
in the next step without further purification. 1H NMR (400 MHz, CDCl3) δ 7.16 (d, J = 7.7 Hz, 
1H), 7.13 – 7.09 (m, 1H), 6.87 (td, J = 7.5, 1.2 Hz, 1H), 6.82 (dd, J = 8.2, 1.2 Hz, 1H), 4.20 – 4.18 
(m, 2H), 3.07 (dd, J = 12.7, 4.7 Hz, 1H), 2.92 (dd, J = 12.7, 8.3 Hz, 1H), 2.83 (dt, J = 13.5, 5.2 
Hz, 1H), 2.11 – 2.05 (m, 1H), 2.03 – 1.97 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 155.2, 129.2, 
127.8, 123.9, 120.4, 117.1, 63.6, 47.2, 37.0, 25.1. HRMS (ESI) calcd for [M+H]+ C10H14NO 
164.1075, found 164.1077. Spectra available at: https://doi.org/10.14469/hpc/5882 
5-Bromo-N-(chroman-4-ylmethyl)thiophene-2-sulfonamide (68). Following general procedure 
C, sulfonamide 68 was obtained from amine 67 (30 mg, 0.18 mmol) and 5-bromothiophene-2-
sulfonyl chloride (53 mg, 0.20 mmol) in 43% yield (30 mg) as pale-yellow oil. Column 
 61 
chromatography: 5-10% of (EtOAc/EtOH, 3:1) in pentane. 1H NMR (400 MHz, CDCl3) δ 7.35 (d, 
J = 4.0 Hz, 1H), 7.17 – 7.11 (m, 1H), 7.07 (d, J = 4.0 Hz, 1H), 7.03 (d, J = 7.6 Hz, 1H), 6.88 – 
6.81 (m, 2H), 4.65 (t, J = 6.5 Hz, 1H, NH), 4.20 – 4.12 (m, 2H), 3.38 – 3.24 (m, 2H), 3.07 – 3.01 
(m, 1H), 2.09 – 2.01 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 155.4, 141.7, 132.4, 130.6, 128.8, 
128.6, 121.4, 120.8, 120.2, 117.6, 63.2, 47.9, 33.8, 24.9. HRMS (ESI) calcd for [M-H]- 
C14H13NO3S2Br 385.9520, found 385.9526. Spectra available at: 
https://doi.org/10.14469/hpc/5874 
3-Bromo-N-(chroman-4-ylmethyl)benzenesulfonamide (69). Following general procedure C, 
sulfonamide 69 was obtained from amine 67 (30 mg, 0.18 mmol) and 3-bromobenzenesulfonyl 
chloride (51 mg, 0.20 mmol) in 68% yield (47 mg) as a colourless oil. Column chromatography: 
5-10% of (EtOAc/EtOH, 3:1) in pentane. 1H NMR (400 MHz, CDCl3) δ 7.99 (t, J = 1.8 Hz, 1H), 
7.77 (ddd, J = 7.9, 1.7, 1.0 Hz, 1H), 7.72 (ddd, J = 8.0, 1.9, 1.0 Hz, 1H), 7.40 (t, J = 7.9 Hz, 1H), 
7.15 – 7.11 (m, 1H), 7.00 (dd, J = 7.7, 1.3 Hz, 1H), 6.84 (ddd, J = 14.5, 7.8, 1.1 Hz, 2H), 4.56 (t, 
J = 6.5 Hz, 1H, NH), 4.20 – 4.10 (m, 3H), 3.31 – 3.19 (m, 3H), 3.04 – 2.98 (m, 1H), 2.11 – 1.99 
(m, 3H). 13C NMR (101 MHz, CDCl3) δ 155.4, 141.9, 136.0, 130.9, 130.1, 128.8, 128.6, 125.7, 
123.4, 121.5, 120.7, 117.6, 63.2, 47.7, 33.9, 24.8. HRMS (ESI) calcd for [M-H]- C16H15NO3SBr 
379.9956, found 379.9945. Spectra available at: https://doi.org/10.14469/hpc/5875 
tert-Butyl ((4-hydroxychroman-4-yl)methyl)carbamate (70). To a stirred solution of 
aminoalcohol 2 (365 mg, 2.00 mmol) in DCM (12 mL), Et3N (0.6 mL, 4 mmol) was added 
dropwise. The resulting mixture was cooled down to 0 ºC before di-tert-butyl dicarbonate (533 
mg, 2.40 mmol) was added, and the mixture was stirred at rt for 5 h. Water was added and the 
mixture extracted with DCM (2x), dried over MgSO4, filtered and evaporated under reduced 
pressure to afford protected amine 70 in quantitative yield (559 mg) as a pale-yellow oil. 1H NMR 
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(400 MHz, CDCl3) δ 7.43 (dd, J = 7.8, 1.4 Hz, 1H), 7.19 (ddd, J = 8.7, 7.4, 1.6 Hz, 1H), 6.94 (td, 
J = 7.7, 1.2 Hz, 1H), 6.83 (dd, J = 8.2, 1.1 Hz, 1H), 4.93 (br s, 1H, NH), 4.29 – 4.23 (m, 2H), 3.58 
– 3.47 (m, 2H), 2.90 (br s, 1H, OH), 2.18 – 2.12 (m, 1H), 2.06 – 1.99 (m, 1H), 1.45 (s, 9H). 13C 
NMR (101 MHz, CDCl3) δ 157.2, 154.6, 129.6, 126.7, 126.1, 120.9, 117.2, 80.1, 69.1, 63.6, 49.7, 
33.3, 28.5. HRMS (ESI) calcd for [M+ACN+Na]+ C17H24N2O4Na 343.1634, found 343.1630. 
Spectra available at: https://doi.org/10.14469/hpc/5883 
tert-Butyl ((4-methoxychroman-4-yl)methyl)carbamate (71). Potassium tert-butoxide (125 mg, 
1.11 mmol) was added portion wise to a flask containing anhydrous THF (3 mL) at 0 ºC under 
nitrogen atmosphere, followed by a solution of Boc-protected amine 70 (259 mg, 0.93 mmol) in 
anhydrous THF (3 mL). After stirring for 15 min at 0 ºC, iodomethane (0.09 mL, 1.40 mmol) was 
added and the mixture was allowed to stir at rt for 2 h. Water was slowly added and the mixture 
extracted with DCM (2x), dried over MgSO4, filtered and evaporated under reduced pressure. The 
crude was purified by flash chromatography (pentane/EtOAc, 95:5 to 9:1) to provide methyl ether 
71 in 70% yield (191 mg) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.27 – 7.25 (m, 2H), 
7.21 – 7.17 (m, 1H), 6.92 (t, J = 7.2 Hz, 1H), 6.84 (dd, J = 8.2, 1.0 Hz, 1H), 4.96 (s, 1H), 4.30 – 
4.25 (m, 2H), 3.68 (dd, J = 14.0, 8.8 Hz, 1H), 3.32 (ddd, J = 14.1, 3.8, 1.1 Hz, 1H), 3.03 (s, 3H), 
2.30 – 2.23 (m, 1H), 1.88 (dt, J = 13.8, 3.4 Hz, 1H), 1.44 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 
156.5, 156.4, 129.5, 127.4, 122.4, 120.5, 117.2, 79.4, 74.4, 64.2, 50.2, 48.7, 28.5, 26.3. HRMS 
(ESI) calcd for [M+ACN+Na]+ C18H26N2O4Na 357.1790, found 357.1788. Spectra available at: 
https://doi.org/10.14469/hpc/5884 
(4-Methoxychroman-4-yl)methanamine (72). TBAF (1M in THF, 5 mL) was added dropwise to 
a solution of Boc-protected amine 71 (150 mg, 0.51 mmol) in anhydrous THF (3 mL) and the 
resulting mixture was stirred under reflux for 24 h. The reaction mixture was diluted with DCM, 
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washed with sat. NaHCO3, dried over MgSO4, filtered and evaporated under reduced pressure. The 
crude was purified by flash chromatography (DCM/10% NH4OH in MeOH, 97:3) to provide 
amine 72 in 39% yield (38 mg) as a colourless oil. 1H NMR (400 MHz, CDCl3) δ 7.30 (dd, J = 
7.8, 1.7 Hz, 1H), 7.19 (ddd, J = 8.3, 7.3, 1.7 Hz, 1H), 6.93 (td, J = 7.7, 1.2 Hz, 1H), 6.84 (dd, J = 
8.2, 1.1 Hz, 1H), 4.30 (ddd, J = 11.2, 6.1, 4.1 Hz, 1H), 4.21 (ddd, J = 11.3, 9.3, 3.2 Hz, 1H), 3.10 
(d, J = 14.9 Hz, 1H), 3.08 (s, 3H), 2.91 (d, J = 13.5 Hz, 1H), 2.29 (ddd, J = 13.6, 9.2, 4.0 Hz, 1H), 
2.05 (ddd, J = 13.9, 6.1, 3.2 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 156.3, 129.3, 127.6, 123.1, 
120.4, 117.2, 74.3, 64.1, 50.8, 50.4, 27.5. HRMS (ESI) calcd for [M+H]+ C11H16NO2 194.1181, 
found 194.1187. Spectra available at: https://doi.org/10.14469/hpc/5885 
5-Bromo-N-((4-methoxychroman-4-yl)methyl)thiophene-2-sulfonamide (73). Following 
general procedure C, sulfonamide 73 was obtained from amine 72 (15 mg, 0.080 mmol) and 5-
bromothiophene-2-sulfonyl chloride (22 mg, 0.085 mmol) in 83% yield (27 mg) as a pale yellow 
solid. Column chromatography: pentane/EtOAc, 9:1. 1H NMR (400 MHz, CDCl3) δ 7.32 (d, J = 
4.0 Hz, 1H), 7.22 – 7.17 (m, 2H), 7.05 (t, J = 3.3 Hz, 1H), 6.93 – 6.89 (m, 1H), 6.84 (dd, J = 8.1, 
0.9 Hz, 1H), 5.10 (dd, J = 9.7, 2.3 Hz, 1H, NH), 4.31 (dt, J = 11.8, 4.3 Hz, 1H), 4.18 (td, J = 11.4, 
2.6 Hz, 1H), 3.41 (dd, J = 12.7, 9.8 Hz, 1H), 3.19 (ddd, J = 12.7, 2.8, 1.4 Hz, 1H), 3.01 (s, 3H), 
2.36 – 2.28 (m, 1H), 2.17 (ddd, J = 14.0, 4.3, 2.6 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 156.6, 
141.9, 132.2, 130.5, 130.1, 127.2, 121.5, 120.8, 120.0, 117.5, 73.9, 64.1, 51.7, 50.3, 25.8. HRMS 
(ESI) m/z calcd for [M-H]- C15H15NO4S2Br 415.9626, found 415.9632. Spectra available at: 
https://doi.org/10.14469/hpc/5876 
3-Bromo-N-((4-methoxychroman-4-yl)methyl)benzenesulfonamide (74). Following general 
procedure C, sulfonamide 74 was obtained from amine 72 (15 mg, 0.080 mmol) and 3-
bromobenzenesulfonyl chloride (22 mg, 0.085 mmol) in 84% yield (27 mg) as a white solid. 
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Column chromatography: pentane/EtOAc, 9:1. 1H NMR (400 MHz, CDCl3) δ 7.98 (t, J = 1.8 Hz, 
1H), 7.75 (ddd, J = 7.9, 1.6, 1.0 Hz, 1H), 7.70 (ddd, J = 8.0, 1.8, 1.0 Hz, 1H), 7.38 (t, J = 7.9 Hz, 
1H), 7.19 (ddd, J = 8.3, 7.3, 1.7 Hz, 1H), 7.14 (dd, J = 7.8, 1.6 Hz, 1H), 6.89 (td, J = 7.8, 1.1 Hz, 
1H), 6.83 (dd, J = 8.2, 1.0 Hz, 1H), 5.02 (dd, J = 9.7, 2.1 Hz, 1H, NH), 4.31 (dt, J = 11.8, 4.3 Hz, 
1H), 4.18 (td, J = 11.5, 2.6 Hz, 1H), 3.39 (dd, J = 12.8, 9.9 Hz, 1H), 3.10 (ddd, J = 12.8, 2.6, 1.5 
Hz, 1H), 3.00 (s, 3H), 2.35 – 2.27 (m, 1H), 2.18 (ddd, J = 14.0, 4.1, 2.7 Hz, 1H). 13C NMR (101 
MHz, CDCl3) δ 156.6, 142.1, 135.9, 130.8, 130.0, 130.0, 127.2, 125.6, 123.3, 121.6, 120.8, 117.4, 
74.1, 64.1, 51.6, 50.3, 25.6. HRMS (ESI) m/z calcd for [M-H]- C17H17NO4SBr 410.0062, found 
410.0070. Spectra available at: https://doi.org/10.14469/hpc/5877 
Chiral resolution was performed on a Chiralpack® IE-3 column using an isocratic gradient of 
hexane/isopropanol, 85:25 to yield (-)-74 and (+)-74. 
(+)-74:D
20 = + 70° (c = 0.37, CDCl3) 
(-)-74:D
20 = - 77° (c = 0.30, CDCl3) 
(4-Fluorochroman-4-yl)methanamine (75). To a stirred solution of aminoalcohol 2 (356 mg, 
1.99 mmol) in DCM (6 mL) at -78 ºC, DAST (0.4 mL, 2.98 mmol) was added dropwise and the 
resulting mixture was allowed to warm up to rt over 3h. The mixture was diluted with DCM, 
washed with 1M NaOH, dried over MgSO4, filtered and evaporated under reduced pressure. The 
crude was purified by flash chromatography (DCM/1% NH4OH in MeOH, 98:2) to afford amine 
75 in 31% yield (113 mg) as a colourless oil. 1H NMR (400 MHz, CDCl3) δ 7.43 (dt, J = 7.8, 1.4 
Hz, 1H), 7.28 – 7.24 (m, 1H), 6.97 (t, J = 7.5 Hz, 1H), 6.88 (d, J = 8.3 Hz, 1H), 4.31 – 4.21 (m, 
2H), 3.39 (dd, J = 13.9, 9.8 Hz, 1H), 3.05 (dd, J = 24.7, 13.9 Hz, 1H), 2.41 – 2.23 (m, 2H), 1.32 
(s, 2H). 13C NMR (101 MHz, CDCl3) δ 155.5 (d, J = 3.2 Hz), 130.6 (d, J = 2.6 Hz), 127.0 (d, J = 
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2.5 Hz), 121.9 (d, J = 20.4 Hz), 121.0 (d, J = 1.9 Hz), 117.5 , 90.8 (d, J = 173.7 Hz), 63.1 (d, J = 
2.7 Hz), 49.3 (d, J = 30.4 Hz), 31.0 (d, J = 21.6 Hz). 19F NMR (377 MHz, CDCl3) δ -136.49 (tdd, 
J = 23.7, 17.5, 9.4 Hz). HRMS (ESI) calcd for [M+H]+ C10H13NOF 182.0981, found 182.0974. 
Spectra available at: https://doi.org/10.14469/hpc/5886 
5-Bromo-N-((4-fluorochroman-4-yl)methyl)thiophene-2-sulfonamide (76). Following general 
procedure C, sulfonamide 76 was obtained from amine 75 (30 mg, 0.17 mmol) and 5-
bromothiophene-2-sulfonyl chloride (48 mg, 0.18 mmol) in 44% yield (30 mg) as a pale yellow 
solid. Column chromatography: pentane/(EtOAc/EtOH, 3:1), 95:5 to 9:1. 1H NMR (400 MHz, 
CDCl3) δ 7.36 (d, J = 4.0 Hz, 1H), 7.31 – 7.27 (m, 2H), 7.08 (d, J = 4.0 Hz, 1H), 6.95 (t, J = 7.5 
Hz, 1H), 6.89 (d, J = 8.6 Hz, 1H), 4.85 (dd, J = 8.6, 4.5 Hz, 1H, NH), 4.28 – 4.21 (m, 2H), 3.64 
(ddd, J = 13.6, 8.8, 4.6 Hz, 1H), 3.45 (ddd, J = 27.2, 13.7, 8.9 Hz, 1H), 2.47 – 2.33 (m, 2H). 13C 
NMR (101 MHz, CDCl3) δ 154.0, 141.5, 132.6, 131.4 (d, J = 2.1 Hz), 130.7, 126.6 (d, J = 2.6 Hz), 
121.2 (d, J = 1.5 Hz), 120.3 (d, J = 34.0 Hz), 117.8, 110.1, 89.8 (d, J = 176.6 Hz), 63.0 (d, J = 3.8 
Hz), 50.0 (d, J = 30.2 Hz), 30.8 (d, J = 21.4 Hz). 19F NMR (377 MHz, CDCl3) δ -136.20 – -136.39 
(m, 1F). HRMS (ESI) m/z calcd for [M-H]- C14H12NO3S2BrF 403.9426, found 403.9431. Spectra 
available at: https://doi.org/10.14469/hpc/5878 
3-Bromo-N-((4-fluorochroman-4-yl)methyl)benzenesulfonamide (77). Following general 
procedure C, sulfonamide 77 was obtained from amine 75 (30 mg, 0.17 mmol) and 3-
bromobenzenesulfonyl chloride (46 mg, 0.18 mmol) in 61% yield (40 mg) as a white solid. 
Column chromatography: pentane/(EtOAc/EtOH, 3:1), 95:5 to 9:1. 1H NMR (400 MHz, CDCl3) 
δ 7.99 (t, J = 1.8 Hz, 1H), 7.77 (ddd, J = 7.9, 1.6, 1.0 Hz, 1H), 7.73 (ddd, J = 8.0, 1.7, 0.9 Hz, 1H), 
7.42 (t, J = 7.9 Hz, 1H), 7.30 – 7.25 (m, 4H), 6.93 (t, J = 7.6 Hz, 1H), 6.88 (d, J = 8.1 Hz, 1H), 
4.80 (dd, J = 8.6, 4.4 Hz, 1H, NH), 4.28 – 4.21 (m, 2H), 3.57 (ddd, J = 13.6, 8.9, 4.6 Hz, 1H), 3.43 
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(ddd, J = 27.3, 13.8, 8.9 Hz, 1H), 2.51 – 2.28 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 155.4, 141.9, 
136.2, 131.4 (d, J = 2.4 Hz), 131.0, 130.0, 126.6 (d, J = 3.1 Hz), 125.6, 123.5, 121,1, 120.3 (d, J = 
20.3 Hz), 117.8, 110.1, 89.9 (d, J = 176.2 Hz), 63.0 (d, J = 4.0 Hz), 49.8 (d, J = 30.1 Hz), 30.7 (d, 
J = 21.4 Hz). 19F NMR (377 MHz, CDCl3) δ -136.60 – -136.79 (m, 1F). HRMS (ESI) m/z calcd 
for [M-H]- C16H14NO3SBrF 397.9862, found 397.9870. Spectra available at: 
https://doi.org/10.14469/hpc/5879 
5-Bromo-N-(anti-(4-hydroxychroman-3-yl)methyl)thiophene-2-sulfonamide (78a), and 5-
bromo-N-(syn-(4-hydroxychroman-3-yl)methyl)thiophene-2-sulfonamide (78b). Following 
general procedure C, sulfonamides 78a and 78b were obtained from a 3:1 mixture of 87a and 87b 
(25 mg, 0.14 mmol) and 5-bromothiophene-2-sulfonyl chloride (40 mg, 0.15 mmol) in 86% yield 
(12 mg) and 88% yield (37 mg) as yellow and white solids, respectively. Column chromatography: 
DCM/1% NH4OH in MeOH, 99:1 to 98:2. 78a: 
1H NMR (400 MHz, MeOD) δ 7.35 (d, J = 4.0 
Hz, 1H), 7.30 (dd, J = 7.7, 1.6 Hz, 1H), 7.18 – 7.13 (m, 2H), 6.91 (td, J = 7.5, 1.1 Hz, 1H), 6.75 
(dd, J = 8.3, 1.0 Hz, 1H), 4.47 (d, J = 4.7 Hz, 1H), 4.28 (dd, J = 11.3, 2.8 Hz, 1H), 4.06 (dd, J = 
10.9, 4.9 Hz, 1H), 2.99 (dd, J = 13.3, 6.5 Hz, 1H), 2.88 (dd, J = 13.3, 8.1 Hz, 1H), 2.14 – 2.07 (m, 
1H). 13C NMR (101 MHz, MeOD) δ 155.4, 143.8, 133.3, 132.0, 131.4, 130.3, 124.6, 121.8, 120.1, 
117.5, 66.2, 65.1, 42.9, 41.9. HRMS (ESI) m/z calcd for [M-H]- C14H13NO4S2Br 401.9469, found 
401.9476. 78b: 1H NMR (400 MHz, CDCl3) δ 7.38 (d, J = 3.9 Hz, 1H), 7.28 – 7.22 (m, 8H), 7.08 
(d, J = 4.0 Hz, 1H), 6.95 (td, J = 7.4, 1.1 Hz, 1H), 6.86 (dd, J = 8.2, 1.0 Hz, 1H), 5.21 (t, J = 6.4 
Hz, 1H), 4.82 (s, 1H), 4.14 – 4.07 (m, 2H), 3.32 (dt, J = 13.3, 7.6 Hz, 1H), 3.24 (dt, J = 13.3, 5.4 
Hz, 1H), 2.35 – 2.27 (m, 1H), 2.09 – 2.08 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 154.3, 141.5, 
132.5, 130.6, 130.4, 130.1, 123.3, 121.2, 120.2, 117.3, 65.3, 63.5, 42.1, 38.1. HRMS (ESI) m/z 
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calcd for [M-H]- C14H13NO4S2Br 401.9469, found 401.9473. Spectra available at: 
https://doi.org/10.14469/hpc/5887 (a) and https://doi.org/10.14469/hpc/5888 (b) 
3-Bromo-N-(anti-(4-hydroxychroman-3-yl)methyl)benzenesulfonamide (79a), and 3-bromo-
N-(syn-(4-hydroxychroman-3-yl)methyl)benzenesulfonamide (79b). Following general 
procedure C, sulfonamides 79a and 79b were obtained from a 3:1 mixture of 87a and 87b  (25 mg, 
0.14 mmol) and 3-bromobenzenesulfonyl chloride (39 mg, 0.15 mmol) in 93% yield (13 mg) and 
77% yield (32 mg) as white solids. Column chromatography: DCM/1% NH4OH in MeOH, 99:1 
to 98:2. 79a: 1H NMR (400 MHz, MeOD) δ 7.96 (t, J = 1.8 Hz, 1H), 7.79 (ddd, J = 3.0, 1.8, 1.0 
Hz, 1H), 7.77 (ddd, J = 3.0, 1.8, 0.9 Hz, 1H), 7.48 (t, J = 7.9 Hz, 1H), 7.29 (dd, J = 7.6, 1.6 Hz, 
1H), 7.15 (ddd, J = 8.6, 7.2, 1.4 Hz, 1H), 6.89 (td, J = 7.5, 1.2 Hz, 1H), 6.74 (dd, J = 8.2, 1.0 Hz, 
1H), 4.45 (d, J = 4.9 Hz, 1H), 4.26 (dd, J = 11.3, 2.8 Hz, 1H), 4.03 (dd, J = 11.6, 5.0 Hz, 1H), 2.92 
(dd, J = 13.4, 6.3 Hz, 1H), 2.81 (dd, J = 13.4, 8.2 Hz, 1H), 2.11 – 2.04 (m, 1H). 13C NMR (101 
MHz, MeOD) δ 155.4, 143.8, 136.6, 132.1, 131.4, 130.7, 130.2, 126.8, 124.6, 123.9, 121.8, 117.4, 
66.2, 65.1, 42.7, 42.1. HRMS (ESI) m/z calcd for [M-H]- C16H15NO4SBr 395.9905, found 
395.9907. 79b: 1H NMR (400 MHz, CDCl3) δ 8.03 (t, J = 1.8 Hz, 1H), 7.81 (ddd, J = 7.9, 1.7, 1.0 
Hz, 1H), 7.72 (ddd, J = 8.0, 1.9, 1.0 Hz, 1H), 7.42 (t, J = 7.9 Hz, 1H), 7.28 – 7.21 (m, 8H), 6.94 
(td, J = 7.4, 1.1 Hz, 1H), 6.85 (dd, J = 8.3, 0.9 Hz, 1H), 5.12 (t, J = 6.6 Hz, 1H), 4.81 (t, J = 2.7 
Hz, 1H), 4.12 – 4.05 (m, 2H), 3.27 (dt, J = 13.4, 7.7 Hz, 1H), 3.16 (dt, J = 13.3, 5.4 Hz, 1H), 2.31 
– 2.24 (m, 1H), 2.14 (d, J = 3.5 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 154.3, 141.8, 136.0, 
130.9, 130.4, 130.2, 130.1, 125.7, 123.4, 123.3, 121.1, 117.2, 65.1, 63.5, 41.8, 38.3. HRMS (ESI) 
m/z calcd for [M-H]- C16H15NO4SBr 395.9905, found 395.9910. Spectra available at: 
https://doi.org/10.14469/hpc/5889 (a) and https://doi.org/10.14469/hpc/5890 (b) 
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5-Bromo-N-((3-hydroxychroman-3-yl)methyl)thiophene-2-sulfonamide (80). Following 
general procedure C, sulfonamide 80 was obtained from amine 88 (15 mg, 0.08 mmol) and 5-
bromothiophene-2-sulfonyl chloride (24 mg, 0.09 mmol) in 15% yield (5 mg) as a white solid. 
Column chromatography: DCM/1% NH4OH in MeOH, 98:2. 
1H NMR (400 MHz, CDCl3) δ 7.37 
(d, J = 4.0 Hz, 1H), 7.14 (ddd, J = 8.1, 7.4, 1.6 Hz, 1H), 7.08 (d, J = 4.0 Hz, 1H), 7.04 (d, J = 7.6 
Hz, 1H), 6.92 (td, J = 7.4, 1.2 Hz, 1H), 6.87 (dd, J = 8.2, 0.9 Hz, 1H), 5.07 (t, J = 6.2 Hz, 1H, NH), 
4.02 (dd, J = 11.0, 1.5 Hz, 1H), 3.93 (d, J = 11.0 Hz, 1H), 3.20 – 3.11 (m, 2H), 2.88, 2.84 (ABq, J 
= 16.7 Hz, 2H), 2.65 (s, 1H, OH). 13C NMR (101 MHz, CDCl3) δ 141.1, 132.7, 130.7, 130.6, 128.2, 
121.9, 120.5, 119.1, 117.0, 110.1, 70.5, 67.8, 48.8, 36.3. HRMS (ESI) m/z calcd for [M-H]- 
C14H13NO4S2Br 401.9469, found 401.9473. Spectra available at: 
https://doi.org/10.14469/hpc/5891 
3-Bromo-N-((3-hydroxychroman-3-yl)methyl)benzenesulfonamide (81). Following general 
procedure C, sulfonamide 81 was obtained from amine 88 (15 mg, 0.08 mmol) and 3-
bromobenzenesulfonyl chloride (24 mg, 0.09 mmol) in 70% yield (23 mg) as a white solid. 
Column chromatography: DCM/1% NH4OH in MeOH, 98:2. 
1H NMR (400 MHz, CDCl3) δ 8.01 
(t, J = 1.8 Hz, 1H), 7.79 (ddd, J = 7.9, 1.7, 1.0 Hz, 1H), 7.73 (ddd, J = 8.0, 1.9, 1.0 Hz, 1H), 7.42 
(t, J = 7.9 Hz, 1H), 7.14 (td, J = 8.2, 1.7 Hz, 1H), 7.03 (d, J = 6.4 Hz, 1H), 6.91 (td, J = 7.4, 1.2 
Hz, 1H), 6.86 (dd, J = 8.2, 0.9 Hz, 1H), 5.07 (t, J = 6.3 Hz, 1H, NH), 4.00 (dd, J = 11.0, 1.1 Hz, 
1H), 3.93 (d, J = 11.0 Hz, 1H), 3.09 (d, J = 6.4 Hz, 2H), 2.85, 2.83 (ABq, J = 17.1 Hz, 2H), 2.72 
(s, 1H, OH). 13C NMR (101 MHz, CDCl3) δ 153.3, 141.5, 136.1, 130.9, 130.5, 130.1, 128.1, 125.7, 
123.4, 121.8, 119.1, 117.0, 70.4, 67.9, 48.7, 36.2. HRMS (ESI) m/z calcd for [M-H]- 
C16H15NO4SBr 395.9905, found 395.9901. Spectra available at: https://doi.org/10.14469/hpc/5892 
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tert-Butyl ((2H-chromen-3-yl)methyl)carbamate (82). Following the same procedure described 
for the synthesis of 70, Boc-protected amine 82 was obtained from amine 84 (1.0 g, 6.2 mmol) in 
83% yield (1.35 g) as a white solid. Column chromatography: pentane/EtOAc, 95:5 to 9:1. 1H 
NMR (400 MHz, CDCl3) δ 7.09 (td, J = 7.9, 1.6 Hz, 1H), 6.96 (dd, J = 7.4, 1.5 Hz, 1H), 6.86 (td, 
J = 7.4, 0.9 Hz, 1H), 6.78 (d, J = 8.0 Hz, 1H), 6.29 (s, 1H), 4.73 (s, 2H), 4.66 (s, 1H, NH), 3.82 (d, 
J = 5.5 Hz, 2H), 1.47 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 156.0, 153.4, 131.9, 129.1, 126.6, 
122.3, 121.6, 120.3, 115.6, 80.0, 66.7, 42.7, 28.5. HRMS (ESI) calcd for [M+ACN+Na]+ 
C17H22N2O3Na 325.1528, found 325.1524. Spectra available at: https://doi.org/10.14469/hpc/5893 
2H-Chromene-3-carbonitrile (83).25 A mixture of 2-hydroxibenzaldehyde (5.0 mL, 47 mmol), 
acrylonitrile (15.4 mL, 235 mmol) and DABCO (1.16 g, 10.3 mmol) was stirred at 90 ºC overnight. 
The resulting mixture was diluted with sat. NaHCO3, extracted with DCM (2x), dried over MgSO4, 
filtered and evaporated under reduced pressure. The crude product was purified by flash 
chromatography (pentane/EtOAc, 98:2) to afford nitrile 83 in 74% yield (5.46 g) as white crystals. 
The spectroscopic data are coincident with those reported.33 1H NMR (400 MHz, CDCl3) δ 7.30 – 
7.25 (m, 1H), 7.18 (s, 1H), 7.10 (dd, J = 7.6, 1.6 Hz, 1H), 6.97 (td, J = 7.5, 1.1 Hz, 1H), 6.87 (d, J 
= 8.2 Hz, 1H), 4.82 (d, J = 1.4 Hz, 2H). Spectra available at: https://doi.org/10.14469/hpc/5894 
(2H-Chromen-3-yl)methanamine (84). Following a literature procedure described for a similar 
product,34 a solution of anhydrous AlCl3 (1.93 g, 14.5 mmol) in dry Et2O (19 mL) was added to a 
suspension of LiAlH4 (549 mg, 14.5 mmol) in dry Et2O (19 mL) at 0 ºC and under nitrogen 
atmosphere. After leaving the mixture to stir for 10 min, a solution of nitrile 83 (1.75 g, 11.1 mmol) 
in dry Et2O (19 mL) was added dropwise, and the reaction mixture was stirred at room temperature 
for 2 hours. The reaction was then cooled down to 0 ºC and carefully quenched with water. The 
pH was adjusted to 9~10 with 8M NaOH, and the resulting mixture was filtered through a pad of 
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celite, washing with EtOAc. The organic layer was separated, and the aqueous layer was extracted 
with EtOAc. The combined organic layers were dried over MgSO4, filtered and evaporated under 
reduced pressure. The crude was purified by flash chromatography (2-5% of (10% NH4OH in 
MeOH) in DCM) to provide amine 84 in 56% yield (1 g) as a pale-yellow solid. 1H NMR (400 
MHz, CDCl3) δ 7.08 (td, J = 7.8, 1.7 Hz, 1H), 6.98 (dd, J = 7.4, 1.6 Hz, 1H), 6.86 (td, J = 7.4, 1.1 
Hz, 1H), 6.79 (br d, J = 8.0 Hz, 1H), 6.34 (s, 1H), 4.76 (d, J = 1.0 Hz, 2H), 3.38 (s, 2H), 1.37 (br 
s, 2H). 13C NMR (101 MHz, CDCl3) δ 153.3, 136.1, 128.7, 126.5, 122.7, 121.5, 118.2, 115.6, 67.3, 
44.3. Spectra available at: https://doi.org/10.14469/hpc/5895 
tert-Butyl (anti-(4-hydroxychroman-3-yl)methyl)carbamate and tert-butyl ((3-
hydroxychroman-3-yl)methyl)carbamate (85 and 86). To a flask charged with Boc-protected 
amine 82 (500 mg, 1.91 mg) at 0 ºC, borane (1M in THF, 3.8 mL) was added dropwise and the 
resulting mixture was stirred at rt for 2 h. Water was then added (3.8 mL) followed by sodium 
perborate tetrahydrate (882 mg, 5.73 mmol) and the resulting mixture was stirred at rt for 2 h. The 
reaction mixture was diluted with water, extracted with EtOAc (2x), washed with brine, dried over 
MgSO4, filtered and evaporated under reduced pressure. NMR of the reaction crude showed a 
mixture of the expected anti-Markovnikov product together with the Markovnikov one in a 2:1 
ratio. The crude was purified by flash chromatography (5-10% of [EtOAc/EtOH, 3:1] in pentane) 
to provide anti-Markovnikov product 85 in 49% yield (260 mg) as a white solid, and Markovnikov 
product 86 in 27% yield (143 mg) as a colourless oil.  
85: 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 7.5 Hz, 1H), 7.18 (t, J = 7.2 Hz, 1H), 6.94 (td, J = 
7.5, 1.1 Hz, 1H), 6.80 (d, J = 8.1 Hz, 1H), 4.81 (br s, 1H, NH), 4.59 (d, J = 6.7 Hz, 1H), 4.25 (dd, 
J = 11.2, 3.0 Hz, 1H), 4.04 (dd, J = 11.1, 7.9 Hz, 1H), 3.38 (dd, J = 13.7, 6.5 Hz, 1H), 3.14 (dt, J 
= 14.5, 5.6 Hz, 1H), 2.94 (br s, 1H, OH), 2.16 (br s, 1H), 1.44 (s, 9H). 13C NMR (101 MHz, CDCl3) 
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δ 156.9, 154.1, 129.4, 129.0, 124.2, 121.0, 116.6, 80.0, 66.2, 65.5, 41.0, 39.5, 28.5. HRMS (ESI) 
calcd for [M+ACN+Na]+ C17H24N2O4Na 343.1634, found 343.1630. Spectra available at: 
https://doi.org/10.14469/hpc/5896 
86: 1H NMR (400 MHz, CDCl3) δ 7.10 (t, J = 7.6 Hz, 1H), 7.04 (d, J = 7.4 Hz, 1H), 6.88 (td, J = 
7.6, 0.7 Hz, 1H), 6.83 (d, J = 8.1 Hz, 1H), 5.16 (br s, 1H, NH), 4.17 (br s, 1H, OH), 3.98 (d, J = 
10.9 Hz, 1H), 3.86 (d, J = 10.9 Hz, 1H), 3.31 (dd, J = 14.7, 5.7 Hz, 1H), 3.19 (dd, J = 14.6, 6.6 
Hz, 1H), 2.82 (s, 2H), 1.46 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 158.2, 153.4, 130.5, 127.8, 
121.4, 120.2, 116.8, 80.6, 70.4, 68.7, 46.7, 36.4, 28.4. HRMS (ESI) calcd for [M+ACN+Na]+ 
C17H24N2O4Na 343.1634, found 343.1632. Spectra available at: https://doi.org/10.14469/hpc/5897 
Anti-3-(Aminomethyl)chroman-4-ol (87a), and syn-3-(aminomethyl)chroman-4-ol (87b). To 
a stirred solution of Boc-protected amine 85 (170 mg, 0.61 mmol) in DCM (3 mL) at 0 ºC, TFA 
(0.9 mL, 1.5 mL/mmol) was added dropwise, and the resulting mixture was stirred at that 
temperature for 30 min. 8M NaOH was added and the mixture was extracted with DCM (2x), dried 
over MgSO4, filtered and evaporated under reduced pressure. The crude was purified by flash 
chromatography (DCM/10% NH4OH in MeOH, 92:8) to provide an inseparable 3:1 anti-/syn- 
mixture of aminoalcohols 87a and 87b in 57% yield (62 mg) as a white solid. 1H NMR (400 MHz, 
CDCl3) (anti-/syn-, 3:1) δ 7.47 – 7.43 (m, 2H, CHsyn, CHanti), 7.21 – 7.15 (m, 2H, CHsyn, CHanti), 
6.97 – 6.93 (m, 2H, CHsyn, CHanti), 6.82 – 6.79 (m, 2H, CHsyn, CHanti), 4.98 (d, J = 4.0 Hz, 1H, 
CHsyn), 4.78 (d, J = 7.7 Hz, 1H, CHanti), 4.19 – 4.14 (m, 3H, CH2syn, ½CH2anti), 3.89 (dd, J = 11.2, 
9.3 Hz, 1H, ½CH2anti), 3.15 – 3.03 (m, 3H, CH2syn, ½CH2anti), 2.70 (dd, J = 12.3, 9.8 Hz, 1H, 
½CH2anti), 2.22 – 2.16 (m, 1H, CHsyn), 2.10 – 2.02 (m, 1H, CHanti), 1.75 (brs, 6H, OHsyn, NH2syn, 
OHanti, NH2anti). 
13C NMR (101 MHz, CDCl3) δ 153.9 (Canti), 153.3 (Csyn), 129.7 (CHsyn), 129.3 
(CHsyn), 129.0 (CHanti), 128.0 (CHanti), 125.1 (Canti), 124.9 (Csyn), 121.0 (CHanti), 120.9 (CHsyn), 
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116.5 (CHsyn), 116.4 (CHanti), 70.0 (CHanti), 66.9 (CHsyn), 65.8 (CH2syn), 65.6 (CH2anti), 43.2 
(CH2anti), 41.6 (CHanti), 41.0 (CH2syn), 38.6 (CHsyn). HRMS (ESI) calcd for [M+H]
+ C10H14NO2 
180.1025, found 180.1030. Spectra available at: https://doi.org/10.14469/hpc/5898 
3-(Aminomethyl)chroman-3-ol (88). Following the same procedure described for the synthesis 
of 87, aminoalcohol 88 was obtained from Boc-protected amine 84 (94 mg, 0.34 mmol) in 33% 
yield (20 mg) as a colourless oil. Column chromatography: DCM/10% NH4OH in MeOH, 95:5 to 
92:8. 1H NMR (400 MHz, CDCl3) δ 7.11 (t, J = 7.7 Hz, 1H), 7.06 (d, J = 7.3 Hz, 1H), 6.89 (dd, J 
= 11.6, 4.2 Hz, 1H), 6.85 (d, J = 8.2 Hz, 1H), 3.94 – 3.89 (m, 2H), 2.90 (d, J = 16.8 Hz, 1H), 2.89 
(d, J = 13.0 Hz, 1H), 2.74 (d, J = 16.4 Hz, 1H), 2.68 (d, J = 13.1 Hz, 1H), 1.81 (s, 3H, OH, NH2). 
13C NMR (101 MHz, MeOD) δ 153.7, 130.5, 127.8, 121.3, 120.3, 116.6, 70.5, 67.7, 47.3, 36.1. 
HRMS (ESI) calcd for [M+H]+ C10H14NO2 180.1025, found 180.1024. Spectra available at: 
https://doi.org/10.14469/hpc/5899 
Biological evaluation 
In vitro P. falciparum NF54 strain culture 
Asexual blood stage (ABS) P. falciparum NF54 strain parasites were cultured to seed 
gametocyte cultures as previously reported.35 Briefly, ABS cultures were routinely maintained at 
4% haematocrit with O+ human blood (NHS National Blood Service), supplemented with 10% 
heparin, between 0.5-5% ring stage parasitemia. Cultures were maintained at 37 °C under 3% 
O2/5% CO2/92%N2 gas (BOC Special Gases) with complete culture medium (RPMI 1640 with 
25mM HEPES (Life Technologies), 50 µg/L hypoxanthine (Sigma), 2 g/L sodium bicarbonate 
(Sigma) and 10% A+ human serum (Interstate Blood-Bank)). Parasitemia was monitored by thin-
film smear and Giemsa staining. 
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Sexual stage gametocyte cultures were induced from ABS cultures at 3% ring stage parasitemia 
and 4% haematocrit, strictly maintaining an atmosphere of 37 °C and 3% O2/5% CO2/92%N2 gas 
(BOC Special Gases). Gametocyte culture medium (prepared as above but supplemented with 5% 
A+ human serum and 5% AlbuMAX II (Life Technologies)) was changed daily without the 
addition of fresh erythrocytes to permit gametocyte production and maturation over a 14-day 
period. Maturity and parasitemia were monitored at 0, 7, and 14 days post-induction by thin smear 
and Giemsa staining. Gametocyte culture viability was determined 14 days post-induction by 
measuring the rate of exflagellation, the production of male gametes, relative to red blood cell 
(RBC) density. Briefly, gamete production was induced by treating a small volume of gametocyte 
culture with ookinete medium (RPMI 1640 with 25 mM HEPES (Life Technologies), 50 µg/L 
hypoxanthine (Sigma), 2 g/L sodium bicarbonate (Sigma) and 100 µM xanthurenic acid), dropping 
the temperature from 37 °C to rt. Exflagellation was determined by counting in a haemocytometer, 
as previously described.35 
P. falciparum dual gamete formation assay (Pf DGFA) 
The DGFA was performed as previously described15,17 in an ‘add-in’ format designed for the 
identification of male-gamete targeted compounds. Since activity for the parent molecule 
DDD01035881 has been demonstrated as male specific (having limited to no activity against 
females), here we only focussed on the male-specific readout from the DGFA. DDD01035881 and 
its derivatives act immediately upon activation of male gamete formation. As such there is no 
requirement for preincubation with gametocyte culture prior to the assay readout. Compounds 
were dispensed into black flat-bottom 384-well plates (Greiner) with a HP D300 Digital Dispenser 
in a dose response from 40 nM to 25 µM and repeated at a targeted concentration range for 
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compounds showing an EC50 < 1000 nM. Plates were normalised to 0.25% DMSO (Honeywell) 
and contained 0.25% DMSO and 20 µM DDD01028076 (a male-gamete targeted hit from the 
HTS17) negative and positive controls, respectively. Gametocyte cultures demonstrating > 0.2% 
exflagellation were diluted to 25 million RBC per mL in gametocyte culture medium. Each well 
of the 384-well plate was plated with 10 µL ookinete medium and then 50 µL dilute gametocyte 
culture, with a total of 1.25 million cells per well, to activate the gamete formation process. Plates 
were immediately cooled at 4 °C for 4 minutes and incubated for a further 5 minutes at 28 °C. 10-
frame time lapses (4 frames per second) of each well were then recorded in a meandering pattern 
across the plate with a Nikon Ti-E widefield microscope at x4 objective, 1.5x zoom, under phase 
contrast.  
Exflagellation counts per well were determined with an automated ICY Bioimage Analysis 
algorithm built to recognise exflagellation centres based on pixel intensity, circularity and size of 
disturbances to the cell monolayer. Counts were converted to a percentage inhibition relative to 
positive (C1) and negative (C2) controls with the following equation: 
% 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = 100 − ((
𝑡𝑒𝑠𝑡 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑 − 𝐶1
𝐶2 − 𝐶1
) 𝑋100)  
The assay was performed with n ≥ 2 and n ≥ 3 technical and biological replicates, respectively, 
demonstrating a Z’ factor ≥ 0.4. Using the % inhibition dose response, EC50s were calculated in 
GraphPad Prism version 8 using the log(inhibitor) vs. response – variable slope (four parameters) 
function. Each EC50 was derived from a curve with an R
2 ≥ 0.95, reported as an average of 
biological replicates ± standard error. 
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Hep G2 cytotoxicity assay 
HepG2 human cells (ATCC® HB-8065™) were grown in complete culture medium 
(Dulbecco’s Modified Eagle Medium (Sigma), 10% foetal bovine serum (Sigma), 1% L-glutamine 
(Sigma) and 1% Penicillin-Streptomycin solution (Sigma)) in flasks coated with 1 µg/cm2 collagen 
(Gibco by Life Technologies). Cells were detached with trypsin (Gibco) and counted with 
FastRead slides (Immune Systems) before diluting to 2.2 x 105 cells per mL in culture medium. 
100 µL cell suspension was plated in each well of a black 96-well plate (Greiner) coated with 
collagen at 1 µg/cm2 and washed with phosphate-buffered saline (Sigma). Cells were left to grow 
at 37 °C and 5% CO2 for 24 hours before treating with either 10 µM compounds or negative and 
positive controls, DMSO (Honeywell) and 50 µM Doxorubicin (Sigma), respectively. All wells 
were normalised to 0.5% DMSO and blanks of media ± Alamar Blue (Thermo Fisher), HepG2 and 
empty wells were included. Cells were incubated with compounds at 37 °C and 5% CO2 for 48 
hours before plating Alamar Blue and incubating for a further 2.5 h at 37 °C. Fluorescence of each 
well was measured using a fluorescence excitation wavelength of 560 nm and emission wavelength 
of 590 nm. Percentage of cytotoxicity was determined using the following equation: 
% 𝐶𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 = 100 − ((
𝑡𝑒𝑠𝑡 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑 − 𝑏𝑙𝑎𝑛𝑘
𝐷𝑀𝑆𝑂 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑏𝑙𝑎𝑛𝑘
) 𝑋100) 
The assay was performed with n ≥ 3 biological replicates, with an average Z’ factor of 0.65 for 
each biological replicate. 
In Vitro Metabolic Profile 
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The half-lives of lead compounds 3, 6, 38, 39, 41 and 74 in mouse microsomes were determined 
by Cyprotex Ltd. Briefly, microsomes (0.5 mg/mL) were incubated with the test compounds (3 
µM) at 37 °C in the presence of the co-factor, NADPH, which initiates the reaction. The reaction 
was terminated by the addition of methanol containing an internal standard. Following 
centrifugation, the supernatant was analysed by LC-MS and the disappearance of test compounds 
was monitored over a 45 min time period. The ln peak area ratio (compound peak area/internal 
standard peak area) is plotted against time and the gradient of the line determined. Metabolic half-
life was calculated by fitting the data to a first-order decay model, and intrinsic clearance (CLint) 
is dependent on the half-life and concentration of protein and was calculated using that data. 
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